Melanoma (English Wikipedia)

Ferri F (2019). "Melanoma". Ferri's clinical advisor 2019 : 5 books in 1. Philadelphia, PA: Elsevier. p. 805. ISBN 978-0-323-52957-0. OCLC 1040695302. Archived from the original on 4 August 2020.
Mohs FE, Mikhail GR (January 1991). Mohs micrographic surgery. W.B. Saunders. pp. 13–14. ISBN 978-0-7216-3415-9. Archived from the original on 7 January 2016.
Cooper S (1844). The First Lines of the Theory and Practice of Surgery: Including the Principle Operations. S.S. and W. Wood. Archived from the original on 4 August 2021. Retrieved 14 December 2017.

businesswire.com

"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Archived from the original on 19 March 2022. Retrieved 19 March 2022 – via Business Wire.

cancer.ca

"Precancerous conditions of the skin". Canadian Cancer Society. Archived from the original on 3 August 2020. Retrieved 26 February 2020.

cancer.gov

"Melanoma Treatment – for health professionals". National Cancer Institute. 26 June 2015. Archived from the original on 4 July 2015. Retrieved 30 June 2015.

seer.cancer.gov

"SEER Stat Fact Sheets: Melanoma of the Skin". NCI. Archived from the original on 6 July 2014.

cancer.org

"Can Melanoma Be Prevented?". Archived from the original on 27 June 2006.
"Key Statistics for Melanoma Skin Cancer". www.cancer.org. Archived from the original on 10 April 2017. Retrieved 10 April 2017.

cbsnews.com

"Immune System Taught To Fight Melanoma". CBSNews. 30 May 2009. Archived from the original on 29 October 2010.

cdc.gov

"CDC - What Are the Symptoms of Skin Cancer?". www.cdc.gov. 26 June 2018. Archived from the original on 7 December 2018. Retrieved 1 February 2019.
Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (June 2015). "Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030". MMWR. Morbidity and Mortality Weekly Report. 64 (21): 591–596. PMC 4584771. PMID 26042651. Archived from the original on 31 May 2017.
"CDC – Skin Cancer Statistics". www.cdc.gov. Archived from the original on 10 April 2017. Retrieved 10 April 2017.

gis.cdc.gov

"USCS Data Visualizations". gis.cdc.gov. Archived from the original on 17 March 2020. Retrieved 7 March 2020. Need to select "melanoma"

choosingwisely.org

American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Dermatology, archived from the original on 1 December 2013, retrieved 5 December 2013, which cites:
- Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. (American Academy of Dermatology) (November 2011). "Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. hdl:20.500.12749/1682. PMID 21868127.

cochrane.org

Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. (October 2005). "Statins and fibrates for preventing melanoma". The Cochrane Database of Systematic Reviews. 2014 (4): CD003697. doi:10.1002/14651858.CD003697.pub2. PMC 11102950. PMID 16235336. Archived from the original on 4 July 2018. Retrieved 3 July 2018.
Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (June 2013). "Interferon alpha for the adjuvant treatment of cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2013 (6): CD008955. doi:10.1002/14651858.CD008955.pub2. PMC 10773707. PMID 23775773. Archived from the original on 12 June 2018. Retrieved 11 June 2018.

curadermbcc.eu

"Can we get skin cancer from tanning beds?". CuradermBCC. 1 September 2022. Archived from the original on 3 September 2022. Retrieved 3 September 2022.

curemelanoma.org

"Interleukin-2 (IL2) for Metastatic Melanoma". Melanoma Research Alliance. Retrieved 5 October 2022.

dermnetnz.org

"Introduction to Dermoscopy". DermNet New Zealand. Archived from the original on 7 May 2009.

doi.org

Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease Injury Incidence Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Kanavy HE, Gerstenblith MR (December 2011). "Ultraviolet radiation and melanoma". Seminars in Cutaneous Medicine and Surgery. 30 (4): 222–228. doi:10.1016/j.sder.2011.08.003 (inactive 1 November 2024). PMID 22123420.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Azoury SC, Lange JR (October 2014). "Epidemiology, risk factors, prevention, and early detection of melanoma". The Surgical Clinics of North America. 94 (5): 945–62, vii. doi:10.1016/j.suc.2014.07.013. PMID 25245960.
Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Fiddler IJ (October 1995). "Melanoma Metastasis". Cancer Control. 2 (5): 398–404. doi:10.1177/107327489500200503. PMID 10862180.
Greene MH (December 1999). "The genetics of hereditary melanoma and nevi. 1998 update". Cancer. 86 (11 Suppl): 2464–2477. doi:10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F. PMID 10630172. S2CID 32817426.
Goydos JS, Shoen SL (2016). "Acral Lentiginous Melanoma". Melanoma. Cancer Treatment and Research. Vol. 167. pp. 321–9. doi:10.1007/978-3-319-22539-5_14. ISBN 978-3-319-22538-8. PMID 26601870.
Boniol M, Autier P, Boyle P, Gandini S (July 2012). "Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis". BMJ. 345: e4757. doi:10.1136/bmj.e4757. PMC 3404185. PMID 22833605.
El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. (WHO International Agency for Research on Cancer Monograph Working Group) (August 2009). "A review of human carcinogens--part D: radiation". The Lancet. Oncology. 10 (8): 751–752. doi:10.1016/S1470-2045(09)70213-X. PMID 19655431.
Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, et al. (January 2015). "The risk of melanoma in airline pilots and cabin crew: a meta-analysis". JAMA Dermatology. 151 (1): 51–58. doi:10.1001/jamadermatol.2014.1077. PMC 4482339. PMID 25188246.
Rünger TM, Farahvash B, Hatvani Z, Rees A (January 2012). "Comparison of DNA damage responses following equimutagenic doses of UVA and UVB: a less effective cell cycle arrest with UVA may render UVA-induced pyrimidine dimers more mutagenic than UVB-induced ones". Photochemical & Photobiological Sciences. 11 (1): 207–215. Bibcode:2012PhPhS..11..207R. doi:10.1039/c1pp05232b. PMID 22005748. S2CID 25209863.
Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. (May 2001). "Ultraviolet A and melanoma: a review". Journal of the American Academy of Dermatology. 44 (5): 837–846. doi:10.1067/mjd.2001.114594. PMID 11312434. S2CID 7655216.
Oliveria SA, Saraiya M, Geller AC, Heneghan MK, Jorgensen C (February 2006). "Sun exposure and risk of melanoma". Archives of Disease in Childhood. 91 (2): 131–138. doi:10.1136/adc.2005.086918. PMC 2082713. PMID 16326797.
Lee JA, Strickland D (May 1980). "Malignant melanoma: social status and outdoor work". British Journal of Cancer. 41 (5): 757–763. doi:10.1038/bjc.1980.138. PMC 2010319. PMID 7426301.
Pion IA, Rigel DS, Garfinkel L, Silverman MK, Kopf AW (January 1995). "Occupation and the risk of malignant melanoma". Cancer. 75 (2 Suppl): 637–644. doi:10.1002/1097-0142(19950115)75:2+<637::aid-cncr2820751404>3.0.co;2-#. PMID 7804988. S2CID 196354681.
Khlat M, Vail A, Parkin M, Green A (May 1992). "Mortality from melanoma in migrants to Australia: variation by age at arrival and duration of stay". American Journal of Epidemiology. 135 (10): 1103–1113. doi:10.1093/oxfordjournals.aje.a116210. PMID 1632422.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–410. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
Halachmi S, Gilchrest BA (March 2001). "Update on genetic events in the pathogenesis of melanoma". Current Opinion in Oncology. 13 (2): 129–136. doi:10.1097/00001622-200103000-00008. PMID 11224711. S2CID 29876528.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–10. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, et al. (April 2009). "Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma". Clinical Cancer Research. 15 (7): 2573–2580. doi:10.1158/1078-0432.CCR-08-2678. PMC 3881546. PMID 19318491.
Bliss JM, Ford D, Swerdlow AJ, Armstrong BK, Cristofolini M, Elwood JM, et al. (August 1995). "Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE)". International Journal of Cancer. 62 (4): 367–376. doi:10.1002/ijc.2910620402. PMID 7635560. S2CID 9539601.
Miller AJ, Mihm MC (July 2006). "Melanoma". The New England Journal of Medicine. 355 (1): 51–65. doi:10.1056/NEJMra052166. PMID 16822996.
Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MC, Sober AJ (December 1987). "Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals". JAMA. 258 (21): 3146–3154. doi:10.1001/jama.258.21.3146. PMID 3312689.
Ciarletta P, Foret L, Ben Amar M (March 2011). "The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis". Journal of the Royal Society, Interface. 8 (56): 345–368. doi:10.1098/rsif.2010.0285. PMC 3030817. PMID 20656740.
Hershkovitz L, Schachter J, Treves AJ, Besser MJ (2010). "Focus on adoptive T cell transfer trials in melanoma". Clinical & Developmental Immunology. 2010: 260267. doi:10.1155/2010/260267. PMC 3018069. PMID 21234353.
Spatz A, Gimotty PA, Cook MG, van den Oord JJ, Desai N, Eggermont AM, et al. (2007). "ASCO Annual Meeting Proceedings Part I. Abstract: Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study". Journal of Clinical Oncology. 25 (18S): 8519. doi:10.1200/jco.2007.25.18_suppl.8519. Archived from the original on 25 July 2011.
Davies MA, Samuels Y (October 2010). "Analysis of the genome to personalize therapy for melanoma". Oncogene. 29 (41): 5545–5555. doi:10.1038/onc.2010.323. PMC 3169242. PMID 20697348.
Sage E, Girard PM, Francesconi S (January 2012). "Unravelling UVA-induced mutagenesis". Photochemical & Photobiological Sciences. 11 (1): 74–80. Bibcode:2012PhPhS..11...74S. doi:10.1039/c1pp05219e. PMID 21901217. S2CID 45189513.
Budden T, Bowden NA (January 2013). "The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis". International Journal of Molecular Sciences. 14 (1): 1132–1151. doi:10.3390/ijms14011132. PMC 3565312. PMID 23303275.
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. (May 2012). "Melanoma genome sequencing reveals frequent PREX2 mutations". Nature. 485 (7399): 502–506. Bibcode:2012Natur.485..502B. doi:10.1038/nature11071. PMC 3367798. PMID 22622578.
Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT, et al. (April 2010). "Analysis of genetic inheritance in a family quartet by whole-genome sequencing". Science. 328 (5978): 636–639. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC 3037280. PMID 20220176.
Campbell CD, Chong JX, Malig M, Ko A, Dumont BL, Han L, et al. (November 2012). "Estimating the human mutation rate using autozygosity in a founder population". Nature Genetics. 44 (11): 1277–1281. doi:10.1038/ng.2418. PMC 3483378. PMID 23001126.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. (August 2017). "A pathology atlas of the human cancer transcriptome". Science. 357 (6352): eaan2507. doi:10.1126/science.aan2507. PMID 28818916. S2CID 206659235.
Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. (March 2018). "Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines". Cell Systems. 6 (3): 271–281.e7. doi:10.1016/j.cels.2018.03.002. PMC 6075717. PMID 29596782.
Leslie MC, Bar-Eli M (January 2005). "Regulation of gene expression in melanoma: new approaches for treatment". Journal of Cellular Biochemistry. 94 (1): 25–38. doi:10.1002/jcb.20296. PMID 15523674. S2CID 23515325.
Bhoumik A, Singha N, O'Connell MJ, Ronai ZA (June 2008). "Regulation of TIP60 by ATF2 modulates ATM activation". The Journal of Biological Chemistry. 283 (25): 17605–17614. doi:10.1074/jbc.M802030200. PMC 2427333. PMID 18397884.
Bhoumik A, Jones N, Ronai Z (March 2004). "Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity". Proceedings of the National Academy of Sciences of the United States of America. 101 (12): 4222–4227. Bibcode:2004PNAS..101.4222B. doi:10.1073/pnas.0400195101. PMC 384722. PMID 15010535.
Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V (April 2008). "The role of ATF-2 in oncogenesis". BioEssays. 30 (4): 314–327. doi:10.1002/bies.20734. PMID 18348191. S2CID 678541.
Huang Y, Minigh J, Miles S, Niles RM (February 2008). "Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition". Journal of Molecular Signaling. 3: 3. doi:10.1186/1750-2187-3-3. PMC 2265711. PMID 18269766.
Parmiani G (March 2016). "Melanoma Cancer Stem Cells: Markers and Functions". Cancers. 8 (3): 34. doi:10.3390/cancers8030034. PMC 4810118. PMID 26978405.
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. (Cancer Genome Atlas Network) (June 2015). "Genomic Classification of Cutaneous Melanoma". Cell. 161 (7): 1681–1696. doi:10.1016/j.cell.2015.05.044. PMC 4580370. PMID 26091043.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. (July 2012). "The role of BRAF V600 mutation in melanoma". Journal of Translational Medicine. 10 (1): 85. doi:10.1186/1479-5876-10-85. PMC 3391993. PMID 22554099.
Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, et al. (October 2019). "Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses". Cell Reports. 29 (3): 573–588.e7. doi:10.1016/j.celrep.2019.09.009. PMC 6939448. PMID 31618628.
McEvoy CR, Xu H, Smith K, Etemadmoghadam D, San Leong H, Choong DY, et al. (May 2019). "Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion". The Journal of Clinical Investigation. 129 (5): 1940–1945. doi:10.1172/JCI123089. PMC 6486352. PMID 30835257.
Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. (May 2014). "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas". Nature Communications. 5 (1): 3116. Bibcode:2014NatCo...5.3116W. doi:10.1038/ncomms4116. PMC 4084638. PMID 24445538.
Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, et al. (November 2016). "NTRK3 kinase fusions in Spitz tumours". The Journal of Pathology. 240 (3): 282–290. doi:10.1002/path.4775. PMC 5071153. PMID 27477320.
Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, et al. (May 2015). "Activating MET kinase rearrangements in melanoma and Spitz tumours". Nature Communications. 6 (1): 7174. Bibcode:2015NatCo...6.7174Y. doi:10.1038/ncomms8174. PMC 4446791. PMID 26013381.
Sarna M, Krzykawska-Serda M, Jakubowska M, Zadlo A, Urbanska K (June 2019). "Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion". Scientific Reports. 9 (1): 9280. Bibcode:2019NatSR...9.9280S. doi:10.1038/s41598-019-45643-9. PMC 6594928. PMID 31243305.
Wurm EM, Soyer HP (October 2010). "Scanning for melanoma". Australian Prescriber. 33: 150–55. doi:10.18773/austprescr.2010.070.
Friedman RJ, Rigel DS, Kopf AW (1985). "Early detection of malignant melanoma: the role of physician examination and self-examination of the skin". CA. 35 (3): 130–151. doi:10.3322/canjclin.35.3.130. PMID 3921200. S2CID 20787489.
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, et al. (December 2018). "Visual inspection for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD013194. doi:10.1002/14651858.CD013194. PMC 6492463. PMID 30521684.
Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, et al. (December 2018). "Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD011902. doi:10.1002/14651858.CD011902.pub2. PMC 6517096. PMID 30521682.
Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Patel L, et al. (Cochrane Skin Group) (December 2018). "Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 12 (12): CD013190. doi:10.1002/14651858.CD013190. PMC 6492459. PMID 30521681.
Mascaro JM, Mascaro JM (November 1998). "The dermatologist's position concerning nevi: a vision ranging from "the ugly duckling" to "little red riding hood"". Archives of Dermatology. 134 (11): 1484–1485. doi:10.1001/archderm.134.11.1484 (inactive 2 December 2024). PMID 9828892.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA (August 2015). "Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours". The Australasian Journal of Dermatology. 56 (3): 227–231. doi:10.1111/ajd.12333. PMID 25827527. S2CID 2510803.
Lin SW, Kaye V, Goldfarb N, Rawal A, Warshaw E (July 2012). "Melanoma tumor seeding after punch biopsy". Dermatologic Surgery. 38 (7 Pt 1): 1083–1085. doi:10.1111/j.1524-4725.2012.02384.x. PMID 22471244. S2CID 3431248.
Martin RC, Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Edwards MJ, et al. (December 2005). "Is incisional biopsy of melanoma harmful?". American Journal of Surgery. 190 (6): 913–917. doi:10.1016/j.amjsurg.2005.08.020. PMID 16307945.
Yamashita Y, Hashimoto I, Abe Y, Seike T, Okawa K, Senzaki Y, et al. (March 2014). "Effect of biopsy technique on the survival rate of malignant melanoma patients". Archives of Plastic Surgery. 41 (2): 122–125. doi:10.5999/aps.2014.41.2.122. PMC 3961608. PMID 24665419.
Mills SE (March 2002). "Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas". Modern Pathology. 15 (3): 264–278. doi:10.1038/modpathol.3880522. PMID 11904342. S2CID 34498802.
Piliang MP (September 2009). "Acral Lentiginous Melanoma". Surgical Pathology Clinics. 2 (3): 535–541. doi:10.1016/j.path.2009.08.005. PMID 26838538.
McKenna JK, Florell SR, Goldman GD, Bowen GM (April 2006). "Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment". Dermatologic Surgery. 32 (4): 493–504. doi:10.1111/j.1524-4725.2006.32102.x. PMID 16681656. S2CID 8312676.
Fleming C (2010). "How to manage patients with lentigo maligna". Melanoma Research. 20: e26. doi:10.1097/01.cmr.0000382797.99333.66. ISSN 0960-8931. S2CID 71464540.
Park HS, Cho KH (April 2010). "Acral lentiginous melanoma in situ: a diagnostic and management challenge". Cancers. 2 (2): 642–652. doi:10.3390/cancers2020642. PMC 3835096. PMID 24281086.
Weight RM, Viator JA, Dale PS, Caldwell CW, Lisle AE (October 2006). "Photoacoustic detection of metastatic melanoma cells in the human circulatory system". Optics Letters. 31 (20): 2998–3000. Bibcode:2006OptL...31.2998W. doi:10.1364/OL.31.002998. PMID 17001379.
Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, et al. (Cochrane Skin Group) (July 2019). "Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2019 (7): CD012806. doi:10.1002/14651858.CD012806.pub2. PMC 6601698. PMID 31260100.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. (November 2017). "Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual". CA. 67 (6): 472–492. doi:10.3322/caac.21409. PMC 5978683. PMID 29028110., citing
Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:563‐585).
Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ, et al. (Cochrane Skin Group) (June 2019). "Screening for reducing morbidity and mortality in malignant melanoma". The Cochrane Database of Systematic Reviews. 2019 (6): CD012352. doi:10.1002/14651858.CD012352.pub2. PMC 6545529. PMID 31157404.
Autier P (October 2005). "Cutaneous malignant melanoma: facts about sunbeds and sunscreen". Expert Review of Anticancer Therapy. 5 (5): 821–833. doi:10.1586/14737140.5.5.821. PMID 16221052. S2CID 6091309.
Clough-Gorr KM, Titus-Ernstoff L, Perry AE, Spencer SK, Ernstoff MS (September 2008). "Exposure to sunlamps, tanning beds, and melanoma risk". Cancer Causes & Control. 19 (7): 659–669. doi:10.1007/s10552-008-9129-6. PMC 6367654. PMID 18273687.
Shihab N, Lim HW (November 2018). "Potential cutaneous carcinogenic risk of exposure to UV nail lamp: A review". Photodermatology, Photoimmunology & Photomedicine. 34 (6): 362–365. doi:10.1111/phpp.12398. PMID 29882991. S2CID 46958616.
O'Sullivan NA, Tait CP (May 2014). "Tanning bed and nail lamp use and the risk of cutaneous malignancy: a review of the literature". The Australasian Journal of Dermatology. 55 (2): 99–106. doi:10.1111/ajd.12145. PMID 24592921. S2CID 206984768.
Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A, et al. (December 2015). "European Code against Cancer 4th Edition: Ultraviolet radiation and cancer". Cancer Epidemiology. 39 (Suppl 1): S75–S83. doi:10.1016/j.canep.2014.12.014. hdl:1765/86460. PMID 26096748.
Burnett ME, Wang SQ (April 2011). "Current sunscreen controversies: a critical review". Photodermatology, Photoimmunology & Photomedicine. 27 (2): 58–67. doi:10.1111/j.1600-0781.2011.00557.x. PMID 21392107. S2CID 29173997.
Planta MB (1 November 2011). "Sunscreen and melanoma: is our prevention message correct?". Journal of the American Board of Family Medicine. 24 (6): 735–739. doi:10.3122/jabfm.2011.06.100178. PMID 22086817. S2CID 1477485.
Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. (October 2005). "Statins and fibrates for preventing melanoma". The Cochrane Database of Systematic Reviews. 2014 (4): CD003697. doi:10.1002/14651858.CD003697.pub2. PMC 11102950. PMID 16235336. Archived from the original on 4 July 2018. Retrieved 3 July 2018.
Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. (November 2006). "Statins, fibrates, and melanoma risk: a systematic review and meta-analysis". Journal of the National Cancer Institute. 98 (21): 1538–1546. doi:10.1093/jnci/djj412. PMID 17077356.
Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, et al. (May 2015). "Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2015 (5): CD010307. doi:10.1002/14651858.CD010307.pub2. PMC 6461196. PMID 25978975.
Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, Möller MG, Cruse CW, et al. (July 2008). "Surgical management of melanoma in situ on chronically sun-damaged skin". Cancer Control. 15 (3): 216–224. doi:10.1177/107327480801500304. PMID 18596673.
Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. (September 1993). "Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial". Annals of Surgery. 218 (3): 262–7, discussion 267–9. doi:10.1097/00000658-199309000-00005. PMC 1242959. PMID 8373269.
Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. (October 2009). "Surgical excision margins for primary cutaneous melanoma". The Cochrane Database of Systematic Reviews. 129 (4): CD004835. doi:10.1002/14651858.CD004835.pub2. PMID 19821334.
Bene NI, Healy C, Coldiron BM (May 2008). "Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases". Dermatologic Surgery. 34 (5): 660–664. doi:10.1111/j.1524-4725.2007.34124.x. PMID 18261099. S2CID 23386371. Cure rate as high as 98% for small melanoma in situ, and as high as 95% noted for lentigo maligna variant of melanona in situ has been reported with Mohs surgery.
Ross MI, Gershenwald JE (May–June 2013). "Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience". Clinics in Dermatology. 31 (3): 298–310. doi:10.1016/j.clindermatol.2012.08.004. PMID 23608449.
American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Dermatology, archived from the original on 1 December 2013, retrieved 5 December 2013, which cites:
- Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. (American Academy of Dermatology) (November 2011). "Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. hdl:20.500.12749/1682. PMID 21868127.
- van Kempen LC, Redpath M, Robert C, Spatz A (November 2014). "Molecular pathology of cutaneous melanoma". Melanoma Management. 1 (2): 151–164. doi:10.2217/mmt.14.23. PMC 6094595. PMID 30190820.
- Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, et al. (February 2013). "A nine-gene signature predicting clinical outcome in cutaneous melanoma". Journal of Cancer Research and Clinical Oncology. 139 (2): 249–258. doi:10.1007/s00432-012-1322-z. PMID 23052696. S2CID 20257709.
- Swanson NA, Lee KK, Gorman A, Lee HN (October 2002). "Biopsy techniques. Diagnosis of melanoma". Dermatologic Clinics. 20 (4): 677–680. doi:10.1016/S0733-8635(02)00025-6. PMID 12380054.
- Thomas D, Bello DM (March 2021). "Adjuvant immunotherapy for melanoma". Journal of Surgical Oncology. 123 (3): 789–797. doi:10.1002/jso.26329. ISSN 0022-4790. PMID 33595889. S2CID 231943836.
- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (January 1996). "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684". Journal of Clinical Oncology. 14 (1): 7–17. doi:10.1200/JCO.1996.14.1.7. PMID 8558223. S2CID 24020903.
- Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (June 2013). "Interferon alpha for the adjuvant treatment of cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2013 (6): CD008955. doi:10.1002/14651858.CD008955.pub2. PMC 10773707. PMID 23775773. Archived from the original on 12 June 2018. Retrieved 11 June 2018.
- Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, et al. (2007). "Interferon-α as an adjuvant therapy for melanoma: an individual patient meta-analysis of randomised trials". J Clin Oncol. 25 (18 Suppl): 8526. doi:10.1200/jco.2007.25.18_suppl.8526.
- Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. (June 2000). "High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190". Journal of Clinical Oncology. 18 (12): 2444–2458. doi:10.1200/JCO.2000.18.12.2444. PMID 10856105.
- Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M (March 2002). "Interferon alfa-2a for melanoma metastases". Lancet. 359 (9310): 978–979. doi:10.1016/S0140-6736(02)08001-7. PMID 11918944. S2CID 33866115.
- Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (February 2018). "Systemic treatments for metastatic cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2 (2): CD011123. doi:10.1002/14651858.CD011123.pub2. PMC 6491081. PMID 29405038.
- Ryden V, El-Naggar AI, Koliadi A, Ladjevardi CO, Digkas E, Valachis A, et al. (29 December 2023). "The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis". Pigment Cell & Melanoma Research. 37 (3): 352–362. doi:10.1111/pcmr.13156. ISSN 1755-1471. PMID 38158376.
- Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A (5 December 2008). "Treatment of Melanoma". Deutsches Ärzteblatt International. 105 (49): 845–851. doi:10.3238/arztebl.2008.0845. ISSN 1866-0452. PMC 2689638. PMID 19561811.
- O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SM, et al. (December 2017). "Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions". Annals of Surgical Oncology. 24 (13): 3842–3849. doi:10.1245/s10434-017-6107-9. PMC 7771340. PMID 29019175. S2CID 28907006.
- Giles MH, Coventry BJ (August 2013). "Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit". Cancer Management and Research. 5: 243–249. doi:10.2147/cmar.s45746. PMC 3753062. PMID 23990731.
- Berger M, Richtig G, Kashofer K, Aigelsreiter A, Richtig E (June 2018). "The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations". Giornale Italiano di Dermatologia e Venereologia. 153 (3): 349–360. doi:10.23736/S0392-0488.18.05970-9. PMID 29600692.
- Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, et al. (September 2018). "Melanoma Cell Death Mechanisms". Chonnam Medical Journal. 54 (3): 135–142. doi:10.4068/cmj.2018.54.3.135. PMC 6165917. PMID 30288368.
- Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. (May 2015). "Metastatic melanoma - a review of current and future treatment options". Acta Dermato-Venereologica. 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039.
- Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. (October 2018). "Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy". Pharmacological Research. 136: 151–159. doi:10.1016/j.phrs.2018.08.019. PMID 30145328. S2CID 207369519.
- Rebecca VW, Herlyn M (2020). "Nongenetic Mechanisms of Drug Resistance in Melanoma". Annual Review of Cancer Biology. 4: 315–330. doi:10.1146/annurev-cancerbio-030419-033533.
- Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. (June 2014). "Melanoma immunotherapy". Cancer Biology & Therapy. 15 (6): 665–674. doi:10.4161/cbt.28555. PMC 4049781. PMID 24651672.
- Dranitsaris G, Zhu X, Adunlin G, Vincent MD (August 2018). "Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs". Expert Review of Pharmacoeconomics & Outcomes Research. 18 (4): 351–357. doi:10.1080/14737167.2018.1467270. PMID 29681201. S2CID 5079628.
- West HJ (April 2015). "JAMA Oncology Patient Page. Immune Checkpoint Inhibitors". JAMA Oncology. 1 (1): 115. doi:10.1001/jamaoncol.2015.0137. PMID 26182315.
- Rosenberg SA, Restifo NP (April 2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–68. Bibcode:2015Sci...348...62R. doi:10.1126/science.aaa4967. PMC 6295668. PMID 25838374.
- Zang YW, Gu XD, Xiang JB, Chen ZY (June 2014). "Clinical application of adoptive T cell therapy in solid tumors". Medical Science Monitor. 20: 953–959. doi:10.12659/msm.890496. PMC 4063985. PMID 24912947.
- Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z (December 2014). "Interventions for melanoma in situ, including lentigo maligna". The Cochrane Database of Systematic Reviews. 2016 (12): CD010308. doi:10.1002/14651858.CD010308.pub2. PMC 11005944. PMID 25526608.
- Johnson TM, Headington JT, Baker SR, Lowe L (November 1997). "Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure". Journal of the American Academy of Dermatology. 37 (5 Pt 1): 758–764. doi:10.1016/S0190-9622(97)70114-2. PMID 9366823.
- Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology. 59 (6): R183–R231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/r183. PMID 24584183. S2CID 18082594.
- Bastiaannet E, Beukema JC, Hoekstra HJ (February 2005). "Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications". Cancer Treatment Reviews. 31 (1): 18–26. doi:10.1016/j.ctrv.2004.09.005. PMID 15707701.
- Homsi J, Kashani-Sabet M, Messina JL, Daud A (October 2005). "Cutaneous melanoma: prognostic factors". Cancer Control. 12 (4): 223–229. doi:10.1177/107327480501200403. PMID 16258493.
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. (August 2001). "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma". Journal of Clinical Oncology. 19 (16): 3635–3648. CiteSeerX 10.1.1.475.6560. doi:10.1200/JCO.2001.19.16.3635. PMID 11504745. Archived from the original on 5 March 2006. Retrieved 31 July 2006.
- Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, et al. (January 2015). "Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies". Journal of the American Academy of Dermatology. 72 (1): 59–70. doi:10.1016/j.jaad.2014.09.029. PMID 25440435.
- Zhan H, Ma JY, Jian QC (September 2018). "Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis". Clinica Chimica Acta; International Journal of Clinical Chemistry. 484: 136–140. doi:10.1016/j.cca.2018.05.055. PMID 29856976. S2CID 44155588.
- Wade RG, Robinson AV, Lo MC, Keeble C, Marples M, Dewar DJ, et al. (October 2018). "Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study". Annals of Surgical Oncology. 25 (11): 3341–3349. doi:10.1245/s10434-018-6660-x. PMC 6132419. PMID 30066226.
- Robinson AV, Keeble C, Lo MC, Thornton O, Peach H, Moncrieff MD, et al. (April 2020). "The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study". Cancer Immunology, Immunotherapy. 69 (4): 559–568. doi:10.1007/s00262-019-02478-7. PMC 7113207. PMID 31974724.
- Berwick M, Wiggins C (May 2006). "The current epidemiology of cutaneous malignant melanoma". Frontiers in Bioscience. 11: 1244–1254. doi:10.2741/1877. PMID 16368510.
- Urteaga O, Pack GT (May 1966). "On the antiquity of melanoma". Cancer. 19 (5): 607–610. doi:10.1002/1097-0142(196605)19:5<607::AID-CNCR2820190502>3.0.CO;2-8. PMID 5326247.
- "Drugs in Clinical Development for Melanoma". Pharmaceutical Medicine. 26 (3): 171–83. 23 December 2012. doi:10.1007/BF03262391. S2CID 13247048. Archived from the original on 1 January 2013. Retrieved 12 June 2012.
- Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM (2002). "Advances in gene therapy for malignant melanoma". Cancer Control. 9 (1): 39–48. doi:10.1177/107327480200900106. PMID 11907465.
- Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. (November 2008). "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens". Journal of Clinical Oncology. 26 (32): 5233–5239. doi:10.1200/JCO.2008.16.5449. PMC 2652090. PMID 18809613.
- Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients" (PDF). Clinical Cancer Research. 16 (9): 2646–2655. doi:10.1158/1078-0432.CCR-10-0041. PMID 20406835. S2CID 32568. Retrieved 15 August 2011.
- Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. (June 2011). "gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma". The New England Journal of Medicine. 364 (22): 2119–2127. doi:10.1056/NEJMoa1012863. PMC 3517182. PMID 21631324.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. (June 2011). "Improved survival with vemurafenib in melanoma with BRAF V600E mutation". The New England Journal of Medicine. 364 (26): 2507–2516. doi:10.1056/NEJMoa1103782. PMC 3549296. PMID 21639808.
- Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. (November 2012). "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations". The New England Journal of Medicine. 367 (18): 1694–1703. doi:10.1056/NEJMoa1210093. PMC 3549295. PMID 23020132.
- Shirley M (August 2018). "Encorafenib and Binimetinib: First Global Approvals". Drugs. 78 (12): 1277–1284. doi:10.1007/s40265-018-0963-x. PMID 30117021. S2CID 52020890.
- Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. (June 2011). "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma". The New England Journal of Medicine. 364 (26): 2517–2526. doi:10.1056/NEJMoa1104621. PMID 21639810.
- Voit C, Van Akkooi AC, Schäfer-Hesterberg G, Schoengen A, Kowalczyk K, Roewert JC, et al. (February 2010). "Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma". Journal of Clinical Oncology. 28 (5): 847–852. doi:10.1200/JCO.2009.25.7428. PMID 20065175.
- Forbes NE, Abdelbary H, Lupien M, Bell JC, Diallo JS (September 2013). "Exploiting tumor epigenetics to improve oncolytic virotherapy". Frontiers in Genetics. 4: 184. doi:10.3389/fgene.2013.00184. PMC 3778850. PMID 24062768.
- Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. (September 2015). "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma". Journal of Clinical Oncology. 33 (25): 2780–2788. doi:10.1200/JCO.2014.58.3377. PMID 26014293. S2CID 23663167.
- Costa B, Vale N (September 2023). "Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions". International Journal of Molecular Sciences. 24 (19): 1615. doi:10.3390/ijms25031615. PMC 10572383. PMID 37834078.
- Müller MD, Holst PJ, Nielsen KN (January 2022). "A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches". International Journal of Molecular Sciences. 23 (3): 1330. doi:10.3390/ijms23031330. PMC 8836156. PMID 35163254.
- Zanrè V, Bellinato F, Cardile A, Passarini C, Monticelli J, Di Bella S, et al. (28 January 2024). "Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines". International Journal of Molecular Sciences. 25 (3): 1615. doi:10.3390/ijms25031615. ISSN 1422-0067. PMC 10855363. PMID 38338893.
- Zanrè V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M (6 November 2024). "BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells". International Journal of Molecular Sciences. 25 (22): 11939. doi:10.3390/ijms252211939. ISSN 1422-0067. PMC 11593403.

dorlands.com

"Dorland's Illustrated Medical Dictionary". Elsevier. Archived from the original on 11 January 2014. Retrieved 20 July 2018.

drugs.com

"Yervoy". Drugs.com. Archived from the original on 9 August 2011.

fda.gov

"FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma". U.S. Food and Drug Administration (Press release). 16 February 2024. Retrieved 18 February 2024.
Jefferson E (25 March 2011). "FDA approves new treatment for a type of late-stage skin cancer" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 27 March 2011. Retrieved 25 March 2011.

figshare.com

aacr.figshare.com

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients" (PDF). Clinical Cancer Research. 16 (9): 2646–2655. doi:10.1158/1078-0432.CCR-10-0041. PMID 20406835. S2CID 32568. Retrieved 15 August 2011.

forbes.com

blogs.forbes.com

"The Risk For Bristol". Forbes. Archived from the original on 15 March 2011.

globenewswire.com

"Iovance's Amtagvi (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma" (Press release). Iovance Biotherapeutics Inc. 16 February 2024. Retrieved 18 February 2024 – via GlobeNewswire.

handle.net

hdl.handle.net

Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A, et al. (December 2015). "European Code against Cancer 4th Edition: Ultraviolet radiation and cancer". Cancer Epidemiology. 39 (Suppl 1): S75–S83. doi:10.1016/j.canep.2014.12.014. hdl:1765/86460. PMID 26096748.
American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Dermatology, archived from the original on 1 December 2013, retrieved 5 December 2013, which cites:
- Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. (American Academy of Dermatology) (November 2011). "Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. hdl:20.500.12749/1682. PMID 21868127.

harvard.edu

ui.adsabs.harvard.edu

Rünger TM, Farahvash B, Hatvani Z, Rees A (January 2012). "Comparison of DNA damage responses following equimutagenic doses of UVA and UVB: a less effective cell cycle arrest with UVA may render UVA-induced pyrimidine dimers more mutagenic than UVB-induced ones". Photochemical & Photobiological Sciences. 11 (1): 207–215. Bibcode:2012PhPhS..11..207R. doi:10.1039/c1pp05232b. PMID 22005748. S2CID 25209863.
Sage E, Girard PM, Francesconi S (January 2012). "Unravelling UVA-induced mutagenesis". Photochemical & Photobiological Sciences. 11 (1): 74–80. Bibcode:2012PhPhS..11...74S. doi:10.1039/c1pp05219e. PMID 21901217. S2CID 45189513.
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. (May 2012). "Melanoma genome sequencing reveals frequent PREX2 mutations". Nature. 485 (7399): 502–506. Bibcode:2012Natur.485..502B. doi:10.1038/nature11071. PMC 3367798. PMID 22622578.
Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT, et al. (April 2010). "Analysis of genetic inheritance in a family quartet by whole-genome sequencing". Science. 328 (5978): 636–639. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC 3037280. PMID 20220176.
Bhoumik A, Jones N, Ronai Z (March 2004). "Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity". Proceedings of the National Academy of Sciences of the United States of America. 101 (12): 4222–4227. Bibcode:2004PNAS..101.4222B. doi:10.1073/pnas.0400195101. PMC 384722. PMID 15010535.
Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. (May 2014). "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas". Nature Communications. 5 (1): 3116. Bibcode:2014NatCo...5.3116W. doi:10.1038/ncomms4116. PMC 4084638. PMID 24445538.
Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, et al. (May 2015). "Activating MET kinase rearrangements in melanoma and Spitz tumours". Nature Communications. 6 (1): 7174. Bibcode:2015NatCo...6.7174Y. doi:10.1038/ncomms8174. PMC 4446791. PMID 26013381.
Sarna M, Krzykawska-Serda M, Jakubowska M, Zadlo A, Urbanska K (June 2019). "Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion". Scientific Reports. 9 (1): 9280. Bibcode:2019NatSR...9.9280S. doi:10.1038/s41598-019-45643-9. PMC 6594928. PMID 31243305.
Weight RM, Viator JA, Dale PS, Caldwell CW, Lisle AE (October 2006). "Photoacoustic detection of metastatic melanoma cells in the human circulatory system". Optics Letters. 31 (20): 2998–3000. Bibcode:2006OptL...31.2998W. doi:10.1364/OL.31.002998. PMID 17001379.
Rosenberg SA, Restifo NP (April 2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–68. Bibcode:2015Sci...348...62R. doi:10.1126/science.aaa4967. PMC 6295668. PMID 25838374.
Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology. 59 (6): R183–R231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/r183. PMID 24584183. S2CID 18082594.

iarc.fr

World Cancer Report (PDF). World Health Organization. 2014. pp. Chapter 5.14. ISBN 978-92-832-0429-9. Archived (PDF) from the original on 30 May 2014.

www-dep.iarc.fr

"CANCERMondial (GLOBOCAN)". GLOBOCAN. 2010. Archived from the original on 17 February 2012. Retrieved 12 August 2010.

jco.org

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. (August 2001). "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma". Journal of Clinical Oncology. 19 (16): 3635–3648. CiteSeerX 10.1.1.475.6560. doi:10.1200/JCO.2001.19.16.3635. PMID 11504745. Archived from the original on 5 March 2006. Retrieved 31 July 2006.

malignant-melanoma.org

"The Sentinel Node Biopsy Procedure in Melanoma does not offer a survival advantage". Malignant Melanoma. 8 January 2008. Archived from the original on 11 July 2012. Retrieved 13 August 2012.
"The Screening and Surveillance of Ultrasound in Melanoma trial (SUNMEL)". Archived from the original on 6 January 2009.
"malignant-melanoma.org". Archived from the original on 14 October 2011.

mayoclinic.org

"Melanoma Risk factors". Mayo Clinic. Archived from the original on 10 April 2017. Retrieved 10 April 2017.

melanomafoundation.org

"Prevention: ABCD's of Melanoma". American Melanoma Foundation. Archived from the original on 23 April 2003.

merriam-webster.com

unabridged.merriam-webster.com

Merriam-Webster, Merriam-Webster's Collegiate Dictionary, Merriam-Webster, archived from the original on 10 October 2020, retrieved 20 July 2018

molemap.co.nz

"The EFG of Nodular Melanomas | MoleMap New Zealand". The EFG of Nodular Melanomas | MoleMap New Zealand. Archived from the original on 2 February 2019. Retrieved 1 February 2019.

news-medical.net

"Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients". News Medical. 1 October 2012. Archived from the original on 14 May 2013.
"Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors". News-medical.net. 9 June 2010. Archived from the original on 19 October 2012. Retrieved 13 August 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Goldstein BG, Goldstein AO (April 2001). "Diagnosis and management of malignant melanoma". American Family Physician. 63 (7): 1359–68, 1374. PMID 11310650.
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease Injury Incidence Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
Kanavy HE, Gerstenblith MR (December 2011). "Ultraviolet radiation and melanoma". Seminars in Cutaneous Medicine and Surgery. 30 (4): 222–228. doi:10.1016/j.sder.2011.08.003 (inactive 1 November 2024). PMID 22123420.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Azoury SC, Lange JR (October 2014). "Epidemiology, risk factors, prevention, and early detection of melanoma". The Surgical Clinics of North America. 94 (5): 945–62, vii. doi:10.1016/j.suc.2014.07.013. PMID 25245960.
Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Daniel Jensen J, Elewski BE (February 2015). "The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations". The Journal of Clinical and Aesthetic Dermatology. 8 (2): 15. PMC 4345927. PMID 25741397.
Fiddler IJ (October 1995). "Melanoma Metastasis". Cancer Control. 2 (5): 398–404. doi:10.1177/107327489500200503. PMID 10862180.
Greene MH (December 1999). "The genetics of hereditary melanoma and nevi. 1998 update". Cancer. 86 (11 Suppl): 2464–2477. doi:10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F. PMID 10630172. S2CID 32817426.
Goydos JS, Shoen SL (2016). "Acral Lentiginous Melanoma". Melanoma. Cancer Treatment and Research. Vol. 167. pp. 321–9. doi:10.1007/978-3-319-22539-5_14. ISBN 978-3-319-22538-8. PMID 26601870.
Perkins A, Duffy RL (June 2015). "Atypical moles: diagnosis and management". American Family Physician. 91 (11): 762–767. PMID 26034853.
Boniol M, Autier P, Boyle P, Gandini S (July 2012). "Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis". BMJ. 345: e4757. doi:10.1136/bmj.e4757. PMC 3404185. PMID 22833605.
El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. (WHO International Agency for Research on Cancer Monograph Working Group) (August 2009). "A review of human carcinogens--part D: radiation". The Lancet. Oncology. 10 (8): 751–752. doi:10.1016/S1470-2045(09)70213-X. PMID 19655431.
Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, et al. (January 2015). "The risk of melanoma in airline pilots and cabin crew: a meta-analysis". JAMA Dermatology. 151 (1): 51–58. doi:10.1001/jamadermatol.2014.1077. PMC 4482339. PMID 25188246.
Rünger TM, Farahvash B, Hatvani Z, Rees A (January 2012). "Comparison of DNA damage responses following equimutagenic doses of UVA and UVB: a less effective cell cycle arrest with UVA may render UVA-induced pyrimidine dimers more mutagenic than UVB-induced ones". Photochemical & Photobiological Sciences. 11 (1): 207–215. Bibcode:2012PhPhS..11..207R. doi:10.1039/c1pp05232b. PMID 22005748. S2CID 25209863.
Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. (May 2001). "Ultraviolet A and melanoma: a review". Journal of the American Academy of Dermatology. 44 (5): 837–846. doi:10.1067/mjd.2001.114594. PMID 11312434. S2CID 7655216.
Oliveria SA, Saraiya M, Geller AC, Heneghan MK, Jorgensen C (February 2006). "Sun exposure and risk of melanoma". Archives of Disease in Childhood. 91 (2): 131–138. doi:10.1136/adc.2005.086918. PMC 2082713. PMID 16326797.
Lee JA, Strickland D (May 1980). "Malignant melanoma: social status and outdoor work". British Journal of Cancer. 41 (5): 757–763. doi:10.1038/bjc.1980.138. PMC 2010319. PMID 7426301.
Pion IA, Rigel DS, Garfinkel L, Silverman MK, Kopf AW (January 1995). "Occupation and the risk of malignant melanoma". Cancer. 75 (2 Suppl): 637–644. doi:10.1002/1097-0142(19950115)75:2+<637::aid-cncr2820751404>3.0.co;2-#. PMID 7804988. S2CID 196354681.
Khlat M, Vail A, Parkin M, Green A (May 1992). "Mortality from melanoma in migrants to Australia: variation by age at arrival and duration of stay". American Journal of Epidemiology. 135 (10): 1103–1113. doi:10.1093/oxfordjournals.aje.a116210. PMID 1632422.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–410. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
Halachmi S, Gilchrest BA (March 2001). "Update on genetic events in the pathogenesis of melanoma". Current Opinion in Oncology. 13 (2): 129–136. doi:10.1097/00001622-200103000-00008. PMID 11224711. S2CID 29876528.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–10. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, et al. (April 2009). "Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma". Clinical Cancer Research. 15 (7): 2573–2580. doi:10.1158/1078-0432.CCR-08-2678. PMC 3881546. PMID 19318491.
Bliss JM, Ford D, Swerdlow AJ, Armstrong BK, Cristofolini M, Elwood JM, et al. (August 1995). "Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE)". International Journal of Cancer. 62 (4): 367–376. doi:10.1002/ijc.2910620402. PMID 7635560. S2CID 9539601.
Miller AJ, Mihm MC (July 2006). "Melanoma". The New England Journal of Medicine. 355 (1): 51–65. doi:10.1056/NEJMra052166. PMID 16822996.
Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MC, Sober AJ (December 1987). "Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals". JAMA. 258 (21): 3146–3154. doi:10.1001/jama.258.21.3146. PMID 3312689.
Ciarletta P, Foret L, Ben Amar M (March 2011). "The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis". Journal of the Royal Society, Interface. 8 (56): 345–368. doi:10.1098/rsif.2010.0285. PMC 3030817. PMID 20656740.
Hershkovitz L, Schachter J, Treves AJ, Besser MJ (2010). "Focus on adoptive T cell transfer trials in melanoma". Clinical & Developmental Immunology. 2010: 260267. doi:10.1155/2010/260267. PMC 3018069. PMID 21234353.
Davies MA, Samuels Y (October 2010). "Analysis of the genome to personalize therapy for melanoma". Oncogene. 29 (41): 5545–5555. doi:10.1038/onc.2010.323. PMC 3169242. PMID 20697348.
Sage E, Girard PM, Francesconi S (January 2012). "Unravelling UVA-induced mutagenesis". Photochemical & Photobiological Sciences. 11 (1): 74–80. Bibcode:2012PhPhS..11...74S. doi:10.1039/c1pp05219e. PMID 21901217. S2CID 45189513.
Budden T, Bowden NA (January 2013). "The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis". International Journal of Molecular Sciences. 14 (1): 1132–1151. doi:10.3390/ijms14011132. PMC 3565312. PMID 23303275.
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. (May 2012). "Melanoma genome sequencing reveals frequent PREX2 mutations". Nature. 485 (7399): 502–506. Bibcode:2012Natur.485..502B. doi:10.1038/nature11071. PMC 3367798. PMID 22622578.
Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT, et al. (April 2010). "Analysis of genetic inheritance in a family quartet by whole-genome sequencing". Science. 328 (5978): 636–639. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC 3037280. PMID 20220176.
Campbell CD, Chong JX, Malig M, Ko A, Dumont BL, Han L, et al. (November 2012). "Estimating the human mutation rate using autozygosity in a founder population". Nature Genetics. 44 (11): 1277–1281. doi:10.1038/ng.2418. PMC 3483378. PMID 23001126.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. (August 2017). "A pathology atlas of the human cancer transcriptome". Science. 357 (6352): eaan2507. doi:10.1126/science.aan2507. PMID 28818916. S2CID 206659235.
Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. (March 2018). "Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines". Cell Systems. 6 (3): 271–281.e7. doi:10.1016/j.cels.2018.03.002. PMC 6075717. PMID 29596782.
Leslie MC, Bar-Eli M (January 2005). "Regulation of gene expression in melanoma: new approaches for treatment". Journal of Cellular Biochemistry. 94 (1): 25–38. doi:10.1002/jcb.20296. PMID 15523674. S2CID 23515325.
Bhoumik A, Singha N, O'Connell MJ, Ronai ZA (June 2008). "Regulation of TIP60 by ATF2 modulates ATM activation". The Journal of Biological Chemistry. 283 (25): 17605–17614. doi:10.1074/jbc.M802030200. PMC 2427333. PMID 18397884.
Bhoumik A, Jones N, Ronai Z (March 2004). "Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity". Proceedings of the National Academy of Sciences of the United States of America. 101 (12): 4222–4227. Bibcode:2004PNAS..101.4222B. doi:10.1073/pnas.0400195101. PMC 384722. PMID 15010535.
Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V (April 2008). "The role of ATF-2 in oncogenesis". BioEssays. 30 (4): 314–327. doi:10.1002/bies.20734. PMID 18348191. S2CID 678541.
Huang Y, Minigh J, Miles S, Niles RM (February 2008). "Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition". Journal of Molecular Signaling. 3: 3. doi:10.1186/1750-2187-3-3. PMC 2265711. PMID 18269766.
Parmiani G (March 2016). "Melanoma Cancer Stem Cells: Markers and Functions". Cancers. 8 (3): 34. doi:10.3390/cancers8030034. PMC 4810118. PMID 26978405.
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. (Cancer Genome Atlas Network) (June 2015). "Genomic Classification of Cutaneous Melanoma". Cell. 161 (7): 1681–1696. doi:10.1016/j.cell.2015.05.044. PMC 4580370. PMID 26091043.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. (July 2012). "The role of BRAF V600 mutation in melanoma". Journal of Translational Medicine. 10 (1): 85. doi:10.1186/1479-5876-10-85. PMC 3391993. PMID 22554099.
Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, et al. (October 2019). "Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses". Cell Reports. 29 (3): 573–588.e7. doi:10.1016/j.celrep.2019.09.009. PMC 6939448. PMID 31618628.
McEvoy CR, Xu H, Smith K, Etemadmoghadam D, San Leong H, Choong DY, et al. (May 2019). "Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion". The Journal of Clinical Investigation. 129 (5): 1940–1945. doi:10.1172/JCI123089. PMC 6486352. PMID 30835257.
Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. (May 2014). "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas". Nature Communications. 5 (1): 3116. Bibcode:2014NatCo...5.3116W. doi:10.1038/ncomms4116. PMC 4084638. PMID 24445538.
Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, et al. (November 2016). "NTRK3 kinase fusions in Spitz tumours". The Journal of Pathology. 240 (3): 282–290. doi:10.1002/path.4775. PMC 5071153. PMID 27477320.
Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, et al. (May 2015). "Activating MET kinase rearrangements in melanoma and Spitz tumours". Nature Communications. 6 (1): 7174. Bibcode:2015NatCo...6.7174Y. doi:10.1038/ncomms8174. PMC 4446791. PMID 26013381.
Sarna M, Krzykawska-Serda M, Jakubowska M, Zadlo A, Urbanska K (June 2019). "Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion". Scientific Reports. 9 (1): 9280. Bibcode:2019NatSR...9.9280S. doi:10.1038/s41598-019-45643-9. PMC 6594928. PMID 31243305.
Friedman RJ, Rigel DS, Kopf AW (1985). "Early detection of malignant melanoma: the role of physician examination and self-examination of the skin". CA. 35 (3): 130–151. doi:10.3322/canjclin.35.3.130. PMID 3921200. S2CID 20787489.
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, et al. (December 2018). "Visual inspection for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD013194. doi:10.1002/14651858.CD013194. PMC 6492463. PMID 30521684.
Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, et al. (December 2018). "Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD011902. doi:10.1002/14651858.CD011902.pub2. PMC 6517096. PMID 30521682.
Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Patel L, et al. (Cochrane Skin Group) (December 2018). "Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 12 (12): CD013190. doi:10.1002/14651858.CD013190. PMC 6492459. PMID 30521681.
Mascaro JM, Mascaro JM (November 1998). "The dermatologist's position concerning nevi: a vision ranging from "the ugly duckling" to "little red riding hood"". Archives of Dermatology. 134 (11): 1484–1485. doi:10.1001/archderm.134.11.1484 (inactive 2 December 2024). PMID 9828892.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
Montgomery BD, Sadler GM (January 2009). "Punch biopsy of pigmented lesions is potentially hazardous". Canadian Family Physician. 55 (1): 24, autor reply 24. PMC 2628830. PMID 19155361.
Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA (August 2015). "Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours". The Australasian Journal of Dermatology. 56 (3): 227–231. doi:10.1111/ajd.12333. PMID 25827527. S2CID 2510803.
Lin SW, Kaye V, Goldfarb N, Rawal A, Warshaw E (July 2012). "Melanoma tumor seeding after punch biopsy". Dermatologic Surgery. 38 (7 Pt 1): 1083–1085. doi:10.1111/j.1524-4725.2012.02384.x. PMID 22471244. S2CID 3431248.
Martin RC, Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Edwards MJ, et al. (December 2005). "Is incisional biopsy of melanoma harmful?". American Journal of Surgery. 190 (6): 913–917. doi:10.1016/j.amjsurg.2005.08.020. PMID 16307945.
Yamashita Y, Hashimoto I, Abe Y, Seike T, Okawa K, Senzaki Y, et al. (March 2014). "Effect of biopsy technique on the survival rate of malignant melanoma patients". Archives of Plastic Surgery. 41 (2): 122–125. doi:10.5999/aps.2014.41.2.122. PMC 3961608. PMID 24665419.
Mills SE (March 2002). "Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas". Modern Pathology. 15 (3): 264–278. doi:10.1038/modpathol.3880522. PMID 11904342. S2CID 34498802.
Xiong M, Charifa A, Chen CS (2020). "Lentigo Maligna Melanoma". Cancer, Lentigo Maligna Melanoma. StatPearls. PMID 29489150. Archived from the original on 8 March 2021. Retrieved 13 February 2020 – via National Center for Biotechnology Information. Last Update: 18 May 2019.
Piliang MP (September 2009). "Acral Lentiginous Melanoma". Surgical Pathology Clinics. 2 (3): 535–541. doi:10.1016/j.path.2009.08.005. PMID 26838538.
McKenna JK, Florell SR, Goldman GD, Bowen GM (April 2006). "Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment". Dermatologic Surgery. 32 (4): 493–504. doi:10.1111/j.1524-4725.2006.32102.x. PMID 16681656. S2CID 8312676.
Park HS, Cho KH (April 2010). "Acral lentiginous melanoma in situ: a diagnostic and management challenge". Cancers. 2 (2): 642–652. doi:10.3390/cancers2020642. PMC 3835096. PMID 24281086.
Weight RM, Viator JA, Dale PS, Caldwell CW, Lisle AE (October 2006). "Photoacoustic detection of metastatic melanoma cells in the human circulatory system". Optics Letters. 31 (20): 2998–3000. Bibcode:2006OptL...31.2998W. doi:10.1364/OL.31.002998. PMID 17001379.
Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, et al. (Cochrane Skin Group) (July 2019). "Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2019 (7): CD012806. doi:10.1002/14651858.CD012806.pub2. PMC 6601698. PMID 31260100.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. (November 2017). "Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual". CA. 67 (6): 472–492. doi:10.3322/caac.21409. PMC 5978683. PMID 29028110., citing
Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:563‐585).
Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ, et al. (Cochrane Skin Group) (June 2019). "Screening for reducing morbidity and mortality in malignant melanoma". The Cochrane Database of Systematic Reviews. 2019 (6): CD012352. doi:10.1002/14651858.CD012352.pub2. PMC 6545529. PMID 31157404.
Autier P (October 2005). "Cutaneous malignant melanoma: facts about sunbeds and sunscreen". Expert Review of Anticancer Therapy. 5 (5): 821–833. doi:10.1586/14737140.5.5.821. PMID 16221052. S2CID 6091309.
Clough-Gorr KM, Titus-Ernstoff L, Perry AE, Spencer SK, Ernstoff MS (September 2008). "Exposure to sunlamps, tanning beds, and melanoma risk". Cancer Causes & Control. 19 (7): 659–669. doi:10.1007/s10552-008-9129-6. PMC 6367654. PMID 18273687.
Shihab N, Lim HW (November 2018). "Potential cutaneous carcinogenic risk of exposure to UV nail lamp: A review". Photodermatology, Photoimmunology & Photomedicine. 34 (6): 362–365. doi:10.1111/phpp.12398. PMID 29882991. S2CID 46958616.
O'Sullivan NA, Tait CP (May 2014). "Tanning bed and nail lamp use and the risk of cutaneous malignancy: a review of the literature". The Australasian Journal of Dermatology. 55 (2): 99–106. doi:10.1111/ajd.12145. PMID 24592921. S2CID 206984768.
Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A, et al. (December 2015). "European Code against Cancer 4th Edition: Ultraviolet radiation and cancer". Cancer Epidemiology. 39 (Suppl 1): S75–S83. doi:10.1016/j.canep.2014.12.014. hdl:1765/86460. PMID 26096748.
Burnett ME, Wang SQ (April 2011). "Current sunscreen controversies: a critical review". Photodermatology, Photoimmunology & Photomedicine. 27 (2): 58–67. doi:10.1111/j.1600-0781.2011.00557.x. PMID 21392107. S2CID 29173997.
Planta MB (1 November 2011). "Sunscreen and melanoma: is our prevention message correct?". Journal of the American Board of Family Medicine. 24 (6): 735–739. doi:10.3122/jabfm.2011.06.100178. PMID 22086817. S2CID 1477485.
Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. (October 2005). "Statins and fibrates for preventing melanoma". The Cochrane Database of Systematic Reviews. 2014 (4): CD003697. doi:10.1002/14651858.CD003697.pub2. PMC 11102950. PMID 16235336. Archived from the original on 4 July 2018. Retrieved 3 July 2018.
Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. (November 2006). "Statins, fibrates, and melanoma risk: a systematic review and meta-analysis". Journal of the National Cancer Institute. 98 (21): 1538–1546. doi:10.1093/jnci/djj412. PMID 17077356.
Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, et al. (May 2015). "Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2015 (5): CD010307. doi:10.1002/14651858.CD010307.pub2. PMC 6461196. PMID 25978975.
Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, Möller MG, Cruse CW, et al. (July 2008). "Surgical management of melanoma in situ on chronically sun-damaged skin". Cancer Control. 15 (3): 216–224. doi:10.1177/107327480801500304. PMID 18596673.
Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. (September 1993). "Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial". Annals of Surgery. 218 (3): 262–7, discussion 267–9. doi:10.1097/00000658-199309000-00005. PMC 1242959. PMID 8373269.
Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. (October 2009). "Surgical excision margins for primary cutaneous melanoma". The Cochrane Database of Systematic Reviews. 129 (4): CD004835. doi:10.1002/14651858.CD004835.pub2. PMID 19821334.
Bene NI, Healy C, Coldiron BM (May 2008). "Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases". Dermatologic Surgery. 34 (5): 660–664. doi:10.1111/j.1524-4725.2007.34124.x. PMID 18261099. S2CID 23386371. Cure rate as high as 98% for small melanoma in situ, and as high as 95% noted for lentigo maligna variant of melanona in situ has been reported with Mohs surgery.
Crowson AN, Haskell H (October 2013). "The role of sentinel lymph-node biopsy in the management of cutaneous melanoma". Giornale Italiano di Dermatologia e Venereologia. 148 (5): 493–499. PMID 24005142.
Ross MI, Gershenwald JE (May–June 2013). "Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience". Clinics in Dermatology. 31 (3): 298–310. doi:10.1016/j.clindermatol.2012.08.004. PMID 23608449.
American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Dermatology, archived from the original on 1 December 2013, retrieved 5 December 2013, which cites:
- Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. (American Academy of Dermatology) (November 2011). "Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. hdl:20.500.12749/1682. PMID 21868127.
- van Kempen LC, Redpath M, Robert C, Spatz A (November 2014). "Molecular pathology of cutaneous melanoma". Melanoma Management. 1 (2): 151–164. doi:10.2217/mmt.14.23. PMC 6094595. PMID 30190820.
- Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, et al. (February 2013). "A nine-gene signature predicting clinical outcome in cutaneous melanoma". Journal of Cancer Research and Clinical Oncology. 139 (2): 249–258. doi:10.1007/s00432-012-1322-z. PMID 23052696. S2CID 20257709.
- Swanson NA, Lee KK, Gorman A, Lee HN (October 2002). "Biopsy techniques. Diagnosis of melanoma". Dermatologic Clinics. 20 (4): 677–680. doi:10.1016/S0733-8635(02)00025-6. PMID 12380054.
- Thomas D, Bello DM (March 2021). "Adjuvant immunotherapy for melanoma". Journal of Surgical Oncology. 123 (3): 789–797. doi:10.1002/jso.26329. ISSN 0022-4790. PMID 33595889. S2CID 231943836.
- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (January 1996). "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684". Journal of Clinical Oncology. 14 (1): 7–17. doi:10.1200/JCO.1996.14.1.7. PMID 8558223. S2CID 24020903.
- Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (June 2013). "Interferon alpha for the adjuvant treatment of cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2013 (6): CD008955. doi:10.1002/14651858.CD008955.pub2. PMC 10773707. PMID 23775773. Archived from the original on 12 June 2018. Retrieved 11 June 2018.
- Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. (June 2000). "High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190". Journal of Clinical Oncology. 18 (12): 2444–2458. doi:10.1200/JCO.2000.18.12.2444. PMID 10856105.
- Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M (March 2002). "Interferon alfa-2a for melanoma metastases". Lancet. 359 (9310): 978–979. doi:10.1016/S0140-6736(02)08001-7. PMID 11918944. S2CID 33866115.
- Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (February 2018). "Systemic treatments for metastatic cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2 (2): CD011123. doi:10.1002/14651858.CD011123.pub2. PMC 6491081. PMID 29405038.
- Ryden V, El-Naggar AI, Koliadi A, Ladjevardi CO, Digkas E, Valachis A, et al. (29 December 2023). "The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis". Pigment Cell & Melanoma Research. 37 (3): 352–362. doi:10.1111/pcmr.13156. ISSN 1755-1471. PMID 38158376.
- Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A (5 December 2008). "Treatment of Melanoma". Deutsches Ärzteblatt International. 105 (49): 845–851. doi:10.3238/arztebl.2008.0845. ISSN 1866-0452. PMC 2689638. PMID 19561811.
- O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SM, et al. (December 2017). "Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions". Annals of Surgical Oncology. 24 (13): 3842–3849. doi:10.1245/s10434-017-6107-9. PMC 7771340. PMID 29019175. S2CID 28907006.
- Giles MH, Coventry BJ (August 2013). "Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit". Cancer Management and Research. 5: 243–249. doi:10.2147/cmar.s45746. PMC 3753062. PMID 23990731.
- Berger M, Richtig G, Kashofer K, Aigelsreiter A, Richtig E (June 2018). "The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations". Giornale Italiano di Dermatologia e Venereologia. 153 (3): 349–360. doi:10.23736/S0392-0488.18.05970-9. PMID 29600692.
- Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, et al. (September 2018). "Melanoma Cell Death Mechanisms". Chonnam Medical Journal. 54 (3): 135–142. doi:10.4068/cmj.2018.54.3.135. PMC 6165917. PMID 30288368.
- Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. (May 2015). "Metastatic melanoma - a review of current and future treatment options". Acta Dermato-Venereologica. 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039.
- Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. (October 2018). "Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy". Pharmacological Research. 136: 151–159. doi:10.1016/j.phrs.2018.08.019. PMID 30145328. S2CID 207369519.
- Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. (June 2014). "Melanoma immunotherapy". Cancer Biology & Therapy. 15 (6): 665–674. doi:10.4161/cbt.28555. PMC 4049781. PMID 24651672.
- Dranitsaris G, Zhu X, Adunlin G, Vincent MD (August 2018). "Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs". Expert Review of Pharmacoeconomics & Outcomes Research. 18 (4): 351–357. doi:10.1080/14737167.2018.1467270. PMID 29681201. S2CID 5079628.
- West HJ (April 2015). "JAMA Oncology Patient Page. Immune Checkpoint Inhibitors". JAMA Oncology. 1 (1): 115. doi:10.1001/jamaoncol.2015.0137. PMID 26182315.
- Buzaid AC (October 2004). "Management of metastatic cutaneous melanoma". Oncology. 18 (11): 1443–50, discussion 1457–9. PMID 15609471.
- Rosenberg SA, Restifo NP (April 2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–68. Bibcode:2015Sci...348...62R. doi:10.1126/science.aaa4967. PMC 6295668. PMID 25838374.
- Zang YW, Gu XD, Xiang JB, Chen ZY (June 2014). "Clinical application of adoptive T cell therapy in solid tumors". Medical Science Monitor. 20: 953–959. doi:10.12659/msm.890496. PMC 4063985. PMID 24912947.
- Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z (December 2014). "Interventions for melanoma in situ, including lentigo maligna". The Cochrane Database of Systematic Reviews. 2016 (12): CD010308. doi:10.1002/14651858.CD010308.pub2. PMC 11005944. PMID 25526608.
- Johnson TM, Headington JT, Baker SR, Lowe L (November 1997). "Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure". Journal of the American Academy of Dermatology. 37 (5 Pt 1): 758–764. doi:10.1016/S0190-9622(97)70114-2. PMID 9366823.
- Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology. 59 (6): R183–R231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/r183. PMID 24584183. S2CID 18082594.
- Bastiaannet E, Beukema JC, Hoekstra HJ (February 2005). "Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications". Cancer Treatment Reviews. 31 (1): 18–26. doi:10.1016/j.ctrv.2004.09.005. PMID 15707701.
- Homsi J, Kashani-Sabet M, Messina JL, Daud A (October 2005). "Cutaneous melanoma: prognostic factors". Cancer Control. 12 (4): 223–229. doi:10.1177/107327480501200403. PMID 16258493.
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. (August 2001). "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma". Journal of Clinical Oncology. 19 (16): 3635–3648. CiteSeerX 10.1.1.475.6560. doi:10.1200/JCO.2001.19.16.3635. PMID 11504745. Archived from the original on 5 March 2006. Retrieved 31 July 2006.
- Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, et al. (January 2015). "Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies". Journal of the American Academy of Dermatology. 72 (1): 59–70. doi:10.1016/j.jaad.2014.09.029. PMID 25440435.
- Zhan H, Ma JY, Jian QC (September 2018). "Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis". Clinica Chimica Acta; International Journal of Clinical Chemistry. 484: 136–140. doi:10.1016/j.cca.2018.05.055. PMID 29856976. S2CID 44155588.
- Wade RG, Robinson AV, Lo MC, Keeble C, Marples M, Dewar DJ, et al. (October 2018). "Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study". Annals of Surgical Oncology. 25 (11): 3341–3349. doi:10.1245/s10434-018-6660-x. PMC 6132419. PMID 30066226.
- Robinson AV, Keeble C, Lo MC, Thornton O, Peach H, Moncrieff MD, et al. (April 2020). "The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study". Cancer Immunology, Immunotherapy. 69 (4): 559–568. doi:10.1007/s00262-019-02478-7. PMC 7113207. PMID 31974724.
- Berwick M, Wiggins C (May 2006). "The current epidemiology of cutaneous malignant melanoma". Frontiers in Bioscience. 11: 1244–1254. doi:10.2741/1877. PMID 16368510.
- Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (June 2015). "Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030". MMWR. Morbidity and Mortality Weekly Report. 64 (21): 591–596. PMC 4584771. PMID 26042651. Archived from the original on 31 May 2017.
- Urteaga O, Pack GT (May 1966). "On the antiquity of melanoma". Cancer. 19 (5): 607–610. doi:10.1002/1097-0142(196605)19:5<607::AID-CNCR2820190502>3.0.CO;2-8. PMID 5326247.
- Bodenham DC (October 1968). "A study of 650 observed malignant melanomas in the South-West region". Annals of the Royal College of Surgeons of England. 43 (4): 218–239. PMC 2312310. PMID 5698493.
- Norris W (October 1820). "Case of Fungoid Disease". Edinburgh Medical and Surgical Journal. 16 (65): 562–565. PMC 5830209. PMID 30332089.
- Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM (2002). "Advances in gene therapy for malignant melanoma". Cancer Control. 9 (1): 39–48. doi:10.1177/107327480200900106. PMID 11907465.
- Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. (November 2008). "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens". Journal of Clinical Oncology. 26 (32): 5233–5239. doi:10.1200/JCO.2008.16.5449. PMC 2652090. PMID 18809613.
- Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients" (PDF). Clinical Cancer Research. 16 (9): 2646–2655. doi:10.1158/1078-0432.CCR-10-0041. PMID 20406835. S2CID 32568. Retrieved 15 August 2011.
- Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. (June 2011). "gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma". The New England Journal of Medicine. 364 (22): 2119–2127. doi:10.1056/NEJMoa1012863. PMC 3517182. PMID 21631324.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. (June 2011). "Improved survival with vemurafenib in melanoma with BRAF V600E mutation". The New England Journal of Medicine. 364 (26): 2507–2516. doi:10.1056/NEJMoa1103782. PMC 3549296. PMID 21639808.
- Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. (November 2012). "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations". The New England Journal of Medicine. 367 (18): 1694–1703. doi:10.1056/NEJMoa1210093. PMC 3549295. PMID 23020132.
- Shirley M (August 2018). "Encorafenib and Binimetinib: First Global Approvals". Drugs. 78 (12): 1277–1284. doi:10.1007/s40265-018-0963-x. PMID 30117021. S2CID 52020890.
- Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. (June 2011). "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma". The New England Journal of Medicine. 364 (26): 2517–2526. doi:10.1056/NEJMoa1104621. PMID 21639810.
- Voit C, Van Akkooi AC, Schäfer-Hesterberg G, Schoengen A, Kowalczyk K, Roewert JC, et al. (February 2010). "Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma". Journal of Clinical Oncology. 28 (5): 847–852. doi:10.1200/JCO.2009.25.7428. PMID 20065175.
- Forbes NE, Abdelbary H, Lupien M, Bell JC, Diallo JS (September 2013). "Exploiting tumor epigenetics to improve oncolytic virotherapy". Frontiers in Genetics. 4: 184. doi:10.3389/fgene.2013.00184. PMC 3778850. PMID 24062768.
- Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. (September 2015). "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma". Journal of Clinical Oncology. 33 (25): 2780–2788. doi:10.1200/JCO.2014.58.3377. PMID 26014293. S2CID 23663167.
- Costa B, Vale N (September 2023). "Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions". International Journal of Molecular Sciences. 24 (19): 1615. doi:10.3390/ijms25031615. PMC 10572383. PMID 37834078.
- Müller MD, Holst PJ, Nielsen KN (January 2022). "A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches". International Journal of Molecular Sciences. 23 (3): 1330. doi:10.3390/ijms23031330. PMC 8836156. PMID 35163254.
- Zanrè V, Bellinato F, Cardile A, Passarini C, Monticelli J, Di Bella S, et al. (28 January 2024). "Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines". International Journal of Molecular Sciences. 25 (3): 1615. doi:10.3390/ijms25031615. ISSN 1422-0067. PMC 10855363. PMID 38338893.
ncbi.nlm.nih.gov
- Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease Injury Incidence Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- Daniel Jensen J, Elewski BE (February 2015). "The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations". The Journal of Clinical and Aesthetic Dermatology. 8 (2): 15. PMC 4345927. PMID 25741397.
- Boniol M, Autier P, Boyle P, Gandini S (July 2012). "Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis". BMJ. 345: e4757. doi:10.1136/bmj.e4757. PMC 3404185. PMID 22833605.
- Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, et al. (January 2015). "The risk of melanoma in airline pilots and cabin crew: a meta-analysis". JAMA Dermatology. 151 (1): 51–58. doi:10.1001/jamadermatol.2014.1077. PMC 4482339. PMID 25188246.
- Oliveria SA, Saraiya M, Geller AC, Heneghan MK, Jorgensen C (February 2006). "Sun exposure and risk of melanoma". Archives of Disease in Childhood. 91 (2): 131–138. doi:10.1136/adc.2005.086918. PMC 2082713. PMID 16326797.
- Lee JA, Strickland D (May 1980). "Malignant melanoma: social status and outdoor work". British Journal of Cancer. 41 (5): 757–763. doi:10.1038/bjc.1980.138. PMC 2010319. PMID 7426301.
- Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–410. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
- "CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)". U.S. National Library of Medicine. Archived from the original on 17 November 2004. Retrieved 4 September 2017.
- Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H (March 2016). "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". Journal of the American Academy of Dermatology. 74 (3): 395–407, quiz 408–10. doi:10.1016/j.jaad.2015.08.038. PMC 4761105. PMID 26892650.
- Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, et al. (April 2009). "Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma". Clinical Cancer Research. 15 (7): 2573–2580. doi:10.1158/1078-0432.CCR-08-2678. PMC 3881546. PMID 19318491.
- Ciarletta P, Foret L, Ben Amar M (March 2011). "The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis". Journal of the Royal Society, Interface. 8 (56): 345–368. doi:10.1098/rsif.2010.0285. PMC 3030817. PMID 20656740.
- Hershkovitz L, Schachter J, Treves AJ, Besser MJ (2010). "Focus on adoptive T cell transfer trials in melanoma". Clinical & Developmental Immunology. 2010: 260267. doi:10.1155/2010/260267. PMC 3018069. PMID 21234353.
- Davies MA, Samuels Y (October 2010). "Analysis of the genome to personalize therapy for melanoma". Oncogene. 29 (41): 5545–5555. doi:10.1038/onc.2010.323. PMC 3169242. PMID 20697348.
- Budden T, Bowden NA (January 2013). "The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis". International Journal of Molecular Sciences. 14 (1): 1132–1151. doi:10.3390/ijms14011132. PMC 3565312. PMID 23303275.
- Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. (May 2012). "Melanoma genome sequencing reveals frequent PREX2 mutations". Nature. 485 (7399): 502–506. Bibcode:2012Natur.485..502B. doi:10.1038/nature11071. PMC 3367798. PMID 22622578.
- Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, Shannon PT, et al. (April 2010). "Analysis of genetic inheritance in a family quartet by whole-genome sequencing". Science. 328 (5978): 636–639. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC 3037280. PMID 20220176.
- Campbell CD, Chong JX, Malig M, Ko A, Dumont BL, Han L, et al. (November 2012). "Estimating the human mutation rate using autozygosity in a founder population". Nature Genetics. 44 (11): 1277–1281. doi:10.1038/ng.2418. PMC 3483378. PMID 23001126.
- Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. (March 2018). "Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines". Cell Systems. 6 (3): 271–281.e7. doi:10.1016/j.cels.2018.03.002. PMC 6075717. PMID 29596782.
- Bhoumik A, Singha N, O'Connell MJ, Ronai ZA (June 2008). "Regulation of TIP60 by ATF2 modulates ATM activation". The Journal of Biological Chemistry. 283 (25): 17605–17614. doi:10.1074/jbc.M802030200. PMC 2427333. PMID 18397884.
- Bhoumik A, Jones N, Ronai Z (March 2004). "Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity". Proceedings of the National Academy of Sciences of the United States of America. 101 (12): 4222–4227. Bibcode:2004PNAS..101.4222B. doi:10.1073/pnas.0400195101. PMC 384722. PMID 15010535.
- Huang Y, Minigh J, Miles S, Niles RM (February 2008). "Retinoic acid decreases ATF-2 phosphorylation and sensitizes melanoma cells to taxol-mediated growth inhibition". Journal of Molecular Signaling. 3: 3. doi:10.1186/1750-2187-3-3. PMC 2265711. PMID 18269766.
- Parmiani G (March 2016). "Melanoma Cancer Stem Cells: Markers and Functions". Cancers. 8 (3): 34. doi:10.3390/cancers8030034. PMC 4810118. PMID 26978405.
- Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. (Cancer Genome Atlas Network) (June 2015). "Genomic Classification of Cutaneous Melanoma". Cell. 161 (7): 1681–1696. doi:10.1016/j.cell.2015.05.044. PMC 4580370. PMID 26091043.
- Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. (July 2012). "The role of BRAF V600 mutation in melanoma". Journal of Translational Medicine. 10 (1): 85. doi:10.1186/1479-5876-10-85. PMC 3391993. PMID 22554099.
- Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, et al. (October 2019). "Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses". Cell Reports. 29 (3): 573–588.e7. doi:10.1016/j.celrep.2019.09.009. PMC 6939448. PMID 31618628.
- McEvoy CR, Xu H, Smith K, Etemadmoghadam D, San Leong H, Choong DY, et al. (May 2019). "Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion". The Journal of Clinical Investigation. 129 (5): 1940–1945. doi:10.1172/JCI123089. PMC 6486352. PMID 30835257.
- Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. (May 2014). "Kinase fusions are frequent in Spitz tumours and spitzoid melanomas". Nature Communications. 5 (1): 3116. Bibcode:2014NatCo...5.3116W. doi:10.1038/ncomms4116. PMC 4084638. PMID 24445538.
- Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, et al. (November 2016). "NTRK3 kinase fusions in Spitz tumours". The Journal of Pathology. 240 (3): 282–290. doi:10.1002/path.4775. PMC 5071153. PMID 27477320.
- Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, et al. (May 2015). "Activating MET kinase rearrangements in melanoma and Spitz tumours". Nature Communications. 6 (1): 7174. Bibcode:2015NatCo...6.7174Y. doi:10.1038/ncomms8174. PMC 4446791. PMID 26013381.
- Sarna M, Krzykawska-Serda M, Jakubowska M, Zadlo A, Urbanska K (June 2019). "Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion". Scientific Reports. 9 (1): 9280. Bibcode:2019NatSR...9.9280S. doi:10.1038/s41598-019-45643-9. PMC 6594928. PMID 31243305.
- Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, et al. (December 2018). "Visual inspection for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD013194. doi:10.1002/14651858.CD013194. PMC 6492463. PMID 30521684.
- Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, et al. (December 2018). "Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD011902. doi:10.1002/14651858.CD011902.pub2. PMC 6517096. PMID 30521682.
- Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Patel L, et al. (Cochrane Skin Group) (December 2018). "Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults". The Cochrane Database of Systematic Reviews. 12 (12): CD013190. doi:10.1002/14651858.CD013190. PMC 6492459. PMID 30521681.
- Montgomery BD, Sadler GM (January 2009). "Punch biopsy of pigmented lesions is potentially hazardous". Canadian Family Physician. 55 (1): 24, autor reply 24. PMC 2628830. PMID 19155361.
- Yamashita Y, Hashimoto I, Abe Y, Seike T, Okawa K, Senzaki Y, et al. (March 2014). "Effect of biopsy technique on the survival rate of malignant melanoma patients". Archives of Plastic Surgery. 41 (2): 122–125. doi:10.5999/aps.2014.41.2.122. PMC 3961608. PMID 24665419.
- Xiong M, Charifa A, Chen CS (2020). "Lentigo Maligna Melanoma". Cancer, Lentigo Maligna Melanoma. StatPearls. PMID 29489150. Archived from the original on 8 March 2021. Retrieved 13 February 2020 – via National Center for Biotechnology Information. Last Update: 18 May 2019.
- Park HS, Cho KH (April 2010). "Acral lentiginous melanoma in situ: a diagnostic and management challenge". Cancers. 2 (2): 642–652. doi:10.3390/cancers2020642. PMC 3835096. PMID 24281086.
- Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, et al. (Cochrane Skin Group) (July 2019). "Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2019 (7): CD012806. doi:10.1002/14651858.CD012806.pub2. PMC 6601698. PMID 31260100.
- Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. (November 2017). "Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual". CA. 67 (6): 472–492. doi:10.3322/caac.21409. PMC 5978683. PMID 29028110., citing
  Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:563‐585).
- Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ, et al. (Cochrane Skin Group) (June 2019). "Screening for reducing morbidity and mortality in malignant melanoma". The Cochrane Database of Systematic Reviews. 2019 (6): CD012352. doi:10.1002/14651858.CD012352.pub2. PMC 6545529. PMID 31157404.
- Clough-Gorr KM, Titus-Ernstoff L, Perry AE, Spencer SK, Ernstoff MS (September 2008). "Exposure to sunlamps, tanning beds, and melanoma risk". Cancer Causes & Control. 19 (7): 659–669. doi:10.1007/s10552-008-9129-6. PMC 6367654. PMID 18273687.
- Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. (October 2005). "Statins and fibrates for preventing melanoma". The Cochrane Database of Systematic Reviews. 2014 (4): CD003697. doi:10.1002/14651858.CD003697.pub2. PMC 11102950. PMID 16235336. Archived from the original on 4 July 2018. Retrieved 3 July 2018.
- Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, et al. (May 2015). "Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2015 (5): CD010307. doi:10.1002/14651858.CD010307.pub2. PMC 6461196. PMID 25978975.
- Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. (September 1993). "Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial". Annals of Surgery. 218 (3): 262–7, discussion 267–9. doi:10.1097/00000658-199309000-00005. PMC 1242959. PMID 8373269.
- van Kempen LC, Redpath M, Robert C, Spatz A (November 2014). "Molecular pathology of cutaneous melanoma". Melanoma Management. 1 (2): 151–164. doi:10.2217/mmt.14.23. PMC 6094595. PMID 30190820.
- Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (June 2013). "Interferon alpha for the adjuvant treatment of cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2013 (6): CD008955. doi:10.1002/14651858.CD008955.pub2. PMC 10773707. PMID 23775773. Archived from the original on 12 June 2018. Retrieved 11 June 2018.
- Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (February 2018). "Systemic treatments for metastatic cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2 (2): CD011123. doi:10.1002/14651858.CD011123.pub2. PMC 6491081. PMID 29405038.
- Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A (5 December 2008). "Treatment of Melanoma". Deutsches Ärzteblatt International. 105 (49): 845–851. doi:10.3238/arztebl.2008.0845. ISSN 1866-0452. PMC 2689638. PMID 19561811.
- O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SM, et al. (December 2017). "Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions". Annals of Surgical Oncology. 24 (13): 3842–3849. doi:10.1245/s10434-017-6107-9. PMC 7771340. PMID 29019175. S2CID 28907006.
- Giles MH, Coventry BJ (August 2013). "Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit". Cancer Management and Research. 5: 243–249. doi:10.2147/cmar.s45746. PMC 3753062. PMID 23990731.
- Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, et al. (September 2018). "Melanoma Cell Death Mechanisms". Chonnam Medical Journal. 54 (3): 135–142. doi:10.4068/cmj.2018.54.3.135. PMC 6165917. PMID 30288368.
- Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. (June 2014). "Melanoma immunotherapy". Cancer Biology & Therapy. 15 (6): 665–674. doi:10.4161/cbt.28555. PMC 4049781. PMID 24651672.
- Rosenberg SA, Restifo NP (April 2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–68. Bibcode:2015Sci...348...62R. doi:10.1126/science.aaa4967. PMC 6295668. PMID 25838374.
- Zang YW, Gu XD, Xiang JB, Chen ZY (June 2014). "Clinical application of adoptive T cell therapy in solid tumors". Medical Science Monitor. 20: 953–959. doi:10.12659/msm.890496. PMC 4063985. PMID 24912947.
- Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z (December 2014). "Interventions for melanoma in situ, including lentigo maligna". The Cochrane Database of Systematic Reviews. 2016 (12): CD010308. doi:10.1002/14651858.CD010308.pub2. PMC 11005944. PMID 25526608.
- Wade RG, Robinson AV, Lo MC, Keeble C, Marples M, Dewar DJ, et al. (October 2018). "Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study". Annals of Surgical Oncology. 25 (11): 3341–3349. doi:10.1245/s10434-018-6660-x. PMC 6132419. PMID 30066226.
- Robinson AV, Keeble C, Lo MC, Thornton O, Peach H, Moncrieff MD, et al. (April 2020). "The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study". Cancer Immunology, Immunotherapy. 69 (4): 559–568. doi:10.1007/s00262-019-02478-7. PMC 7113207. PMID 31974724.
- Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (June 2015). "Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030". MMWR. Morbidity and Mortality Weekly Report. 64 (21): 591–596. PMC 4584771. PMID 26042651. Archived from the original on 31 May 2017.
- Bodenham DC (October 1968). "A study of 650 observed malignant melanomas in the South-West region". Annals of the Royal College of Surgeons of England. 43 (4): 218–239. PMC 2312310. PMID 5698493.
- Norris W (October 1820). "Case of Fungoid Disease". Edinburgh Medical and Surgical Journal. 16 (65): 562–565. PMC 5830209. PMID 30332089.
- Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. (November 2008). "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens". Journal of Clinical Oncology. 26 (32): 5233–5239. doi:10.1200/JCO.2008.16.5449. PMC 2652090. PMID 18809613.
- Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. (June 2011). "gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma". The New England Journal of Medicine. 364 (22): 2119–2127. doi:10.1056/NEJMoa1012863. PMC 3517182. PMID 21631324.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. (June 2011). "Improved survival with vemurafenib in melanoma with BRAF V600E mutation". The New England Journal of Medicine. 364 (26): 2507–2516. doi:10.1056/NEJMoa1103782. PMC 3549296. PMID 21639808.
- Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. (November 2012). "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations". The New England Journal of Medicine. 367 (18): 1694–1703. doi:10.1056/NEJMoa1210093. PMC 3549295. PMID 23020132.
- Forbes NE, Abdelbary H, Lupien M, Bell JC, Diallo JS (September 2013). "Exploiting tumor epigenetics to improve oncolytic virotherapy". Frontiers in Genetics. 4: 184. doi:10.3389/fgene.2013.00184. PMC 3778850. PMID 24062768.
- Costa B, Vale N (September 2023). "Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions". International Journal of Molecular Sciences. 24 (19): 1615. doi:10.3390/ijms25031615. PMC 10572383. PMID 37834078.
- Müller MD, Holst PJ, Nielsen KN (January 2022). "A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches". International Journal of Molecular Sciences. 23 (3): 1330. doi:10.3390/ijms23031330. PMC 8836156. PMID 35163254.
- Zanrè V, Bellinato F, Cardile A, Passarini C, Monticelli J, Di Bella S, et al. (28 January 2024). "Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines". International Journal of Molecular Sciences. 25 (3): 1615. doi:10.3390/ijms25031615. ISSN 1422-0067. PMC 10855363. PMID 38338893.
- Zanrè V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M (6 November 2024). "BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells". International Journal of Molecular Sciences. 25 (22): 11939. doi:10.3390/ijms252211939. ISSN 1422-0067. PMC 11593403.
nih.gov
- "New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma; Technique May Also Apply to Other Common Cancers". 30 December 2015. Archived from the original on 28 September 2006.

nytimes.com

Harmon A (21 February 2010). "A Roller Coaster Chase for a Cure". The New York Times. Archived from the original on 10 February 2017.
Pollack A (5 June 2011). "Drugs Show Promise Slowing Advanced Melanoma". The New York Times. Archived from the original on 31 January 2017.
Pollack A (25 March 2011). "Approval for Drug That Treats Melanoma". The New York Times. Archived from the original on 1 April 2011. Retrieved 27 March 2011.

onclive.com

"Dabrafenib/Trametinib Combination Approved for Advanced Melanoma". OncLive. 9 January 2014. Archived from the original on 25 January 2014. Retrieved 4 February 2015.

oncotherapynetwork.com

"Counteracting Drug Resistance in Melanoma". 2015. Archived from the original on 4 February 2015.

pathologyoutlines.com

Hale CS. "Skin melanocytic tumor - Melanoma - Melanoma in situ". pathology Outlines. Archived from the original on 26 February 2020. Retrieved 26 February 2020. Topic Completed: 1 May 2013. Revised: 23 May 2019

proteinatlas.org

"The human pathology proteome in melanoma – The Human Protein Atlas". www.proteinatlas.org. Archived from the original on 2 October 2017. Retrieved 2 October 2017.

psu.edu

citeseerx.ist.psu.edu

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. (August 2001). "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma". Journal of Clinical Oncology. 19 (16): 3635–3648. CiteSeerX 10.1.1.475.6560. doi:10.1200/JCO.2001.19.16.3635. PMID 11504745. Archived from the original on 5 March 2006. Retrieved 31 July 2006.

reuters.com

"GSK melanoma drugs add to tally of U.S. drug approvals". Reuters. 30 May 2013. Archived from the original on 24 September 2015.
"Bristol drug cuts death risk in advanced melanoma". Reuters. 5 June 2010. Archived from the original on 9 November 2010.

semanticscholar.org

api.semanticscholar.org

Greene MH (December 1999). "The genetics of hereditary melanoma and nevi. 1998 update". Cancer. 86 (11 Suppl): 2464–2477. doi:10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F. PMID 10630172. S2CID 32817426.
Rünger TM, Farahvash B, Hatvani Z, Rees A (January 2012). "Comparison of DNA damage responses following equimutagenic doses of UVA and UVB: a less effective cell cycle arrest with UVA may render UVA-induced pyrimidine dimers more mutagenic than UVB-induced ones". Photochemical & Photobiological Sciences. 11 (1): 207–215. Bibcode:2012PhPhS..11..207R. doi:10.1039/c1pp05232b. PMID 22005748. S2CID 25209863.
Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, et al. (May 2001). "Ultraviolet A and melanoma: a review". Journal of the American Academy of Dermatology. 44 (5): 837–846. doi:10.1067/mjd.2001.114594. PMID 11312434. S2CID 7655216.
Pion IA, Rigel DS, Garfinkel L, Silverman MK, Kopf AW (January 1995). "Occupation and the risk of malignant melanoma". Cancer. 75 (2 Suppl): 637–644. doi:10.1002/1097-0142(19950115)75:2+<637::aid-cncr2820751404>3.0.co;2-#. PMID 7804988. S2CID 196354681.
Halachmi S, Gilchrest BA (March 2001). "Update on genetic events in the pathogenesis of melanoma". Current Opinion in Oncology. 13 (2): 129–136. doi:10.1097/00001622-200103000-00008. PMID 11224711. S2CID 29876528.
Bliss JM, Ford D, Swerdlow AJ, Armstrong BK, Cristofolini M, Elwood JM, et al. (August 1995). "Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE)". International Journal of Cancer. 62 (4): 367–376. doi:10.1002/ijc.2910620402. PMID 7635560. S2CID 9539601.
Sage E, Girard PM, Francesconi S (January 2012). "Unravelling UVA-induced mutagenesis". Photochemical & Photobiological Sciences. 11 (1): 74–80. Bibcode:2012PhPhS..11...74S. doi:10.1039/c1pp05219e. PMID 21901217. S2CID 45189513.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. (August 2017). "A pathology atlas of the human cancer transcriptome". Science. 357 (6352): eaan2507. doi:10.1126/science.aan2507. PMID 28818916. S2CID 206659235.
Leslie MC, Bar-Eli M (January 2005). "Regulation of gene expression in melanoma: new approaches for treatment". Journal of Cellular Biochemistry. 94 (1): 25–38. doi:10.1002/jcb.20296. PMID 15523674. S2CID 23515325.
Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V (April 2008). "The role of ATF-2 in oncogenesis". BioEssays. 30 (4): 314–327. doi:10.1002/bies.20734. PMID 18348191. S2CID 678541.
Friedman RJ, Rigel DS, Kopf AW (1985). "Early detection of malignant melanoma: the role of physician examination and self-examination of the skin". CA. 35 (3): 130–151. doi:10.3322/canjclin.35.3.130. PMID 3921200. S2CID 20787489.
Luk PP, Vilain R, Crainic O, McCarthy SW, Thompson JF, Scolyer RA (August 2015). "Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours". The Australasian Journal of Dermatology. 56 (3): 227–231. doi:10.1111/ajd.12333. PMID 25827527. S2CID 2510803.
Lin SW, Kaye V, Goldfarb N, Rawal A, Warshaw E (July 2012). "Melanoma tumor seeding after punch biopsy". Dermatologic Surgery. 38 (7 Pt 1): 1083–1085. doi:10.1111/j.1524-4725.2012.02384.x. PMID 22471244. S2CID 3431248.
Mills SE (March 2002). "Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas". Modern Pathology. 15 (3): 264–278. doi:10.1038/modpathol.3880522. PMID 11904342. S2CID 34498802.
McKenna JK, Florell SR, Goldman GD, Bowen GM (April 2006). "Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment". Dermatologic Surgery. 32 (4): 493–504. doi:10.1111/j.1524-4725.2006.32102.x. PMID 16681656. S2CID 8312676.
Fleming C (2010). "How to manage patients with lentigo maligna". Melanoma Research. 20: e26. doi:10.1097/01.cmr.0000382797.99333.66. ISSN 0960-8931. S2CID 71464540.
Autier P (October 2005). "Cutaneous malignant melanoma: facts about sunbeds and sunscreen". Expert Review of Anticancer Therapy. 5 (5): 821–833. doi:10.1586/14737140.5.5.821. PMID 16221052. S2CID 6091309.
Shihab N, Lim HW (November 2018). "Potential cutaneous carcinogenic risk of exposure to UV nail lamp: A review". Photodermatology, Photoimmunology & Photomedicine. 34 (6): 362–365. doi:10.1111/phpp.12398. PMID 29882991. S2CID 46958616.
O'Sullivan NA, Tait CP (May 2014). "Tanning bed and nail lamp use and the risk of cutaneous malignancy: a review of the literature". The Australasian Journal of Dermatology. 55 (2): 99–106. doi:10.1111/ajd.12145. PMID 24592921. S2CID 206984768.
Burnett ME, Wang SQ (April 2011). "Current sunscreen controversies: a critical review". Photodermatology, Photoimmunology & Photomedicine. 27 (2): 58–67. doi:10.1111/j.1600-0781.2011.00557.x. PMID 21392107. S2CID 29173997.
Planta MB (1 November 2011). "Sunscreen and melanoma: is our prevention message correct?". Journal of the American Board of Family Medicine. 24 (6): 735–739. doi:10.3122/jabfm.2011.06.100178. PMID 22086817. S2CID 1477485.
Bene NI, Healy C, Coldiron BM (May 2008). "Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases". Dermatologic Surgery. 34 (5): 660–664. doi:10.1111/j.1524-4725.2007.34124.x. PMID 18261099. S2CID 23386371. Cure rate as high as 98% for small melanoma in situ, and as high as 95% noted for lentigo maligna variant of melanona in situ has been reported with Mohs surgery.
Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, et al. (February 2013). "A nine-gene signature predicting clinical outcome in cutaneous melanoma". Journal of Cancer Research and Clinical Oncology. 139 (2): 249–258. doi:10.1007/s00432-012-1322-z. PMID 23052696. S2CID 20257709.
Thomas D, Bello DM (March 2021). "Adjuvant immunotherapy for melanoma". Journal of Surgical Oncology. 123 (3): 789–797. doi:10.1002/jso.26329. ISSN 0022-4790. PMID 33595889. S2CID 231943836.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (January 1996). "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684". Journal of Clinical Oncology. 14 (1): 7–17. doi:10.1200/JCO.1996.14.1.7. PMID 8558223. S2CID 24020903.
Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M (March 2002). "Interferon alfa-2a for melanoma metastases". Lancet. 359 (9310): 978–979. doi:10.1016/S0140-6736(02)08001-7. PMID 11918944. S2CID 33866115.
O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SM, et al. (December 2017). "Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions". Annals of Surgical Oncology. 24 (13): 3842–3849. doi:10.1245/s10434-017-6107-9. PMC 7771340. PMID 29019175. S2CID 28907006.
Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. (October 2018). "Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy". Pharmacological Research. 136: 151–159. doi:10.1016/j.phrs.2018.08.019. PMID 30145328. S2CID 207369519.
Dranitsaris G, Zhu X, Adunlin G, Vincent MD (August 2018). "Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs". Expert Review of Pharmacoeconomics & Outcomes Research. 18 (4): 351–357. doi:10.1080/14737167.2018.1467270. PMID 29681201. S2CID 5079628.
Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (March 2014). "Advances in kilovoltage x-ray beam dosimetry". Physics in Medicine and Biology. 59 (6): R183–R231. Bibcode:2014PMB....59R.183H. doi:10.1088/0031-9155/59/6/r183. PMID 24584183. S2CID 18082594.
Zhan H, Ma JY, Jian QC (September 2018). "Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis". Clinica Chimica Acta; International Journal of Clinical Chemistry. 484: 136–140. doi:10.1016/j.cca.2018.05.055. PMID 29856976. S2CID 44155588.
"Drugs in Clinical Development for Melanoma". Pharmaceutical Medicine. 26 (3): 171–83. 23 December 2012. doi:10.1007/BF03262391. S2CID 13247048. Archived from the original on 1 January 2013. Retrieved 12 June 2012.
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients" (PDF). Clinical Cancer Research. 16 (9): 2646–2655. doi:10.1158/1078-0432.CCR-10-0041. PMID 20406835. S2CID 32568. Retrieved 15 August 2011.
Shirley M (August 2018). "Encorafenib and Binimetinib: First Global Approvals". Drugs. 78 (12): 1277–1284. doi:10.1007/s40265-018-0963-x. PMID 30117021. S2CID 52020890.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. (September 2015). "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma". Journal of Clinical Oncology. 33 (25): 2780–2788. doi:10.1200/JCO.2014.58.3377. PMID 26014293. S2CID 23663167.

thefreedictionary.com

medical-dictionary.thefreedictionary.com

Farlex Partner Medical Dictionary. 2012. Archived from the original on 10 June 2022. Retrieved 4 March 2021. Avoid the redundant phrase malignant melanoma.

tufts.edu

perseus.tufts.edu

Liddell HG, Scott R. "μέλας". A Greek-English Lexicon. Perseus. Archived from the original on 5 June 2011.

web.archive.org

"Melanoma Treatment – for health professionals". National Cancer Institute. 26 June 2015. Archived from the original on 4 July 2015. Retrieved 30 June 2015.
World Cancer Report (PDF). World Health Organization. 2014. pp. Chapter 5.14. ISBN 978-92-832-0429-9. Archived (PDF) from the original on 30 May 2014.
"SEER Stat Fact Sheets: Melanoma of the Skin". NCI. Archived from the original on 6 July 2014.
Farlex Partner Medical Dictionary. 2012. Archived from the original on 10 June 2022. Retrieved 4 March 2021. Avoid the redundant phrase malignant melanoma.
"USCS Data Visualizations". gis.cdc.gov. Archived from the original on 17 March 2020. Retrieved 7 March 2020. Need to select "melanoma"
"CDC - What Are the Symptoms of Skin Cancer?". www.cdc.gov. 26 June 2018. Archived from the original on 7 December 2018. Retrieved 1 February 2019.
"The EFG of Nodular Melanomas | MoleMap New Zealand". The EFG of Nodular Melanomas | MoleMap New Zealand. Archived from the original on 2 February 2019. Retrieved 1 February 2019.
"Melanoma Risk factors". Mayo Clinic. Archived from the original on 10 April 2017. Retrieved 10 April 2017.
"WHO | The World Health Organization recommends that no person under 18 should use a sunbed". WHO. Archived from the original on 16 June 2009.
"Can we get skin cancer from tanning beds?". CuradermBCC. 1 September 2022. Archived from the original on 3 September 2022. Retrieved 3 September 2022.
"CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)". U.S. National Library of Medicine. Archived from the original on 17 November 2004. Retrieved 4 September 2017.
Spatz A, Gimotty PA, Cook MG, van den Oord JJ, Desai N, Eggermont AM, et al. (2007). "ASCO Annual Meeting Proceedings Part I. Abstract: Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study". Journal of Clinical Oncology. 25 (18S): 8519. doi:10.1200/jco.2007.25.18_suppl.8519. Archived from the original on 25 July 2011.
"The human pathology proteome in melanoma – The Human Protein Atlas". www.proteinatlas.org. Archived from the original on 2 October 2017. Retrieved 2 October 2017.
"Prevention: ABCD's of Melanoma". American Melanoma Foundation. Archived from the original on 23 April 2003.
"Introduction to Dermoscopy". DermNet New Zealand. Archived from the original on 7 May 2009.
Ferri F (2019). "Melanoma". Ferri's clinical advisor 2019 : 5 books in 1. Philadelphia, PA: Elsevier. p. 805. ISBN 978-0-323-52957-0. OCLC 1040695302. Archived from the original on 4 August 2020.
Xiong M, Charifa A, Chen CS (2020). "Lentigo Maligna Melanoma". Cancer, Lentigo Maligna Melanoma. StatPearls. PMID 29489150. Archived from the original on 8 March 2021. Retrieved 13 February 2020 – via National Center for Biotechnology Information. Last Update: 18 May 2019.
"Precancerous conditions of the skin". Canadian Cancer Society. Archived from the original on 3 August 2020. Retrieved 26 February 2020.
Hale CS. "Skin melanocytic tumor - Melanoma - Melanoma in situ". pathology Outlines. Archived from the original on 26 February 2020. Retrieved 26 February 2020. Topic Completed: 1 May 2013. Revised: 23 May 2019
"Can Melanoma Be Prevented?". Archived from the original on 27 June 2006.
Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. (October 2005). "Statins and fibrates for preventing melanoma". The Cochrane Database of Systematic Reviews. 2014 (4): CD003697. doi:10.1002/14651858.CD003697.pub2. PMC 11102950. PMID 16235336. Archived from the original on 4 July 2018. Retrieved 3 July 2018.
"The Sentinel Node Biopsy Procedure in Melanoma does not offer a survival advantage". Malignant Melanoma. 8 January 2008. Archived from the original on 11 July 2012. Retrieved 13 August 2012.
Mohs FE, Mikhail GR (January 1991). Mohs micrographic surgery. W.B. Saunders. pp. 13–14. ISBN 978-0-7216-3415-9. Archived from the original on 7 January 2016.
"The Screening and Surveillance of Ultrasound in Melanoma trial (SUNMEL)". Archived from the original on 6 January 2009.
American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Dermatology, archived from the original on 1 December 2013, retrieved 5 December 2013, which cites:
- Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. (American Academy of Dermatology) (November 2011). "Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology". Journal of the American Academy of Dermatology. 65 (5): 1032–1047. doi:10.1016/j.jaad.2011.04.031. hdl:20.500.12749/1682. PMID 21868127.
- Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (June 2013). "Interferon alpha for the adjuvant treatment of cutaneous melanoma". The Cochrane Database of Systematic Reviews. 2013 (6): CD008955. doi:10.1002/14651858.CD008955.pub2. PMC 10773707. PMID 23775773. Archived from the original on 12 June 2018. Retrieved 11 June 2018.
- "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Archived from the original on 19 March 2022. Retrieved 19 March 2022 – via Business Wire.
- Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. (August 2001). "Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma". Journal of Clinical Oncology. 19 (16): 3635–3648. CiteSeerX 10.1.1.475.6560. doi:10.1200/JCO.2001.19.16.3635. PMID 11504745. Archived from the original on 5 March 2006. Retrieved 31 July 2006.
- "CANCERMondial (GLOBOCAN)". GLOBOCAN. 2010. Archived from the original on 17 February 2012. Retrieved 12 August 2010.
- "Cancer in Australia: an overview 2012". AIHW. Archived from the original on 2 June 2014. Retrieved 1 June 2014.
- Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC (June 2015). "Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030". MMWR. Morbidity and Mortality Weekly Report. 64 (21): 591–596. PMC 4584771. PMID 26042651. Archived from the original on 31 May 2017.
- "CDC – Skin Cancer Statistics". www.cdc.gov. Archived from the original on 10 April 2017. Retrieved 10 April 2017.
- "Key Statistics for Melanoma Skin Cancer". www.cancer.org. Archived from the original on 10 April 2017. Retrieved 10 April 2017.
- Cooper S (1844). The First Lines of the Theory and Practice of Surgery: Including the Principle Operations. S.S. and W. Wood. Archived from the original on 4 August 2021. Retrieved 14 December 2017.
- Merriam-Webster, Merriam-Webster's Collegiate Dictionary, Merriam-Webster, archived from the original on 10 October 2020, retrieved 20 July 2018
- Liddell HG, Scott R. "μέλας". A Greek-English Lexicon. Perseus. Archived from the original on 5 June 2011.
- "Dorland's Illustrated Medical Dictionary". Elsevier. Archived from the original on 11 January 2014. Retrieved 20 July 2018.
- "The American Heritage Dictionary of the English Language". Houghton Mifflin Harcourt. Archived from the original on 25 September 2015. Retrieved 20 July 2018.
- "New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma; Technique May Also Apply to Other Common Cancers". 30 December 2015. Archived from the original on 28 September 2006.
- "Immune System Taught To Fight Melanoma". CBSNews. 30 May 2009. Archived from the original on 29 October 2010.
- Harmon A (21 February 2010). "A Roller Coaster Chase for a Cure". The New York Times. Archived from the original on 10 February 2017.
- Pollack A (5 June 2011). "Drugs Show Promise Slowing Advanced Melanoma". The New York Times. Archived from the original on 31 January 2017.
- "GSK melanoma drugs add to tally of U.S. drug approvals". Reuters. 30 May 2013. Archived from the original on 24 September 2015.
- "Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients". News Medical. 1 October 2012. Archived from the original on 14 May 2013.
- "Dabrafenib/Trametinib Combination Approved for Advanced Melanoma". OncLive. 9 January 2014. Archived from the original on 25 January 2014. Retrieved 4 February 2015.
- "Counteracting Drug Resistance in Melanoma". 2015. Archived from the original on 4 February 2015.
- "Bristol drug cuts death risk in advanced melanoma". Reuters. 5 June 2010. Archived from the original on 9 November 2010.
- "The Risk For Bristol". Forbes. Archived from the original on 15 March 2011.
- "Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors". News-medical.net. 9 June 2010. Archived from the original on 19 October 2012. Retrieved 13 August 2012.
- Jefferson E (25 March 2011). "FDA approves new treatment for a type of late-stage skin cancer" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 27 March 2011. Retrieved 25 March 2011.
- Pollack A (25 March 2011). "Approval for Drug That Treats Melanoma". The New York Times. Archived from the original on 1 April 2011. Retrieved 27 March 2011.
- "Yervoy". Drugs.com. Archived from the original on 9 August 2011.
- "malignant-melanoma.org". Archived from the original on 14 October 2011.

who.int

"WHO | The World Health Organization recommends that no person under 18 should use a sunbed". WHO. Archived from the original on 16 June 2009.

wiley.com

onlinelibrary.wiley.com

Thomas D, Bello DM (March 2021). "Adjuvant immunotherapy for melanoma". Journal of Surgical Oncology. 123 (3): 789–797. doi:10.1002/jso.26329. ISSN 0022-4790. PMID 33595889. S2CID 231943836.

worldcat.org

search.worldcat.org

Ferri F (2019). "Melanoma". Ferri's clinical advisor 2019 : 5 books in 1. Philadelphia, PA: Elsevier. p. 805. ISBN 978-0-323-52957-0. OCLC 1040695302. Archived from the original on 4 August 2020.
Fleming C (2010). "How to manage patients with lentigo maligna". Melanoma Research. 20: e26. doi:10.1097/01.cmr.0000382797.99333.66. ISSN 0960-8931. S2CID 71464540.
Thomas D, Bello DM (March 2021). "Adjuvant immunotherapy for melanoma". Journal of Surgical Oncology. 123 (3): 789–797. doi:10.1002/jso.26329. ISSN 0022-4790. PMID 33595889. S2CID 231943836.
Ryden V, El-Naggar AI, Koliadi A, Ladjevardi CO, Digkas E, Valachis A, et al. (29 December 2023). "The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis". Pigment Cell & Melanoma Research. 37 (3): 352–362. doi:10.1111/pcmr.13156. ISSN 1755-1471. PMID 38158376.
Garbe C, Terheyden P, Keilholz U, Kölbl O, Hauschild A (5 December 2008). "Treatment of Melanoma". Deutsches Ärzteblatt International. 105 (49): 845–851. doi:10.3238/arztebl.2008.0845. ISSN 1866-0452. PMC 2689638. PMID 19561811.
Zanrè V, Bellinato F, Cardile A, Passarini C, Monticelli J, Di Bella S, et al. (28 January 2024). "Lamivudine, Doravirine, and Cabotegravir Downregulate the Expression of Human Endogenous Retroviruses (HERVs), Inhibit Cell Growth, and Reduce Invasive Capability in Melanoma Cell Lines". International Journal of Molecular Sciences. 25 (3): 1615. doi:10.3390/ijms25031615. ISSN 1422-0067. PMC 10855363. PMID 38338893.
Zanrè V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M (6 November 2024). "BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells". International Journal of Molecular Sciences. 25 (22): 11939. doi:10.3390/ijms252211939. ISSN 1422-0067. PMC 11593403.

wustl.edu

digitalcommons.wustl.edu

Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. (May 2015). "Metastatic melanoma - a review of current and future treatment options". Acta Dermato-Venereologica. 95 (5): 516–524. doi:10.2340/00015555-2035. PMID 25520039.